Note: Descriptions are shown in the official language in which they were submitted.
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
CALCILYTIC COMPOUNDS
FIELD OF INVENTION
The present invention relates to novel calcilytic compounds, pharmaceutical
compositions containing these compounds and their use as calcium receptor
antagonists.
In mammals, extracellular Ca2+ is under rigid homeostatic control and
regulates
various processes such as blood clotting, nerve and muscle excitability, and
proper bone
formation. Extracellular Ca2+ inhibits the secretion of parathyroid hormone
("PTH") from
parathyroid cells, inhibits bone resorption by osteoclasts, and stimulates
secretion of
calcitonin from C-cells. Calcium receptor proteins enable certain specialized
cells to
respond to changes in extracellular Ca2+ concentration.
PTH is the principal endocrine factor regulating Ca2+ homeostasis in the blood
and
extracellular fluids. 1'TI-i, by acting on bone and kidney cells, increases
the level of Ca2+
in the blood. This increase in extracellular Ca2+ then acts as a negative
feedback signal,
depressing P'TH secretion. The reciprocal relationship between extracellular
Ca2+ and
PTH secretion forms an important mechanism maintaining bodily Ca2+
homeostasis.
Extracellular Ca2+ acts directly on parathyroid cells to regulate P'TH
secretion.
The existence of a parathyroid cell surface protein which detects changes in
extracellular
Ca2+ has been confirmed. See Brown et al., Nature 366:574, 1993. In
parathyroid cells,
this protein, the calcium receptor, acts as a receptor for extracellular Ca2+,
detects changes
in the ion concentration of extracellular Ca2+ , and initiates a functional
cellular response,
PTH secretion.
Extracellular Ca2+ influences various cell functions, reviewed in Nemeth et
al.,
Cell Calcium 11:319, 1990. For example, extracellular Ca2+ plays a role in
parafollicular
(C-cells) and parathyroid cells. See Nemeth, Cell Calcium 11:323, 1990. The
role of
extracellular Ca2+ on bone osteoclasts has also been studied. See Zaidi,
Bioscience
Reports 10:493, 1990.
Various compounds are known to mimic the effects of extra-cellular Ca2+ on a
calcium receptor molecule. Calcilytics are compounds able to inhibit calcium
receptor
activity, thereby causing a decrease in one or more calcium receptor
activities evoked by
extracellular Ca2+ . Calcilytics are useful as lead molecules in the
discovery, development,
design, modification and/or construction of useful calcium modulators which
are active at
Ca2+ receptors. Such calcilytics are useful in the treatment of various
disease states
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
characterized by abnormal levels of one or more components, e.g., polypeptides
such as '
hormones, enzymes or growth factors, the expression and/or secretion of which
is regulated
or affected by activity at one or more Ca2+ receptors. Target diseases or
disorders for
calcilytic compounds include diseases involving abnormal bone and mineral
homeostasis.
Abnormal calcium homeostasis is characterized by one or more of the following
activities: an abnormal increase or decrease in serum calcium; an abnormal
increase or
decrease in urinary excretion of calcium; an abnormal increase or decrease in
bone calcium
levels (for example, as assessed by bone mineral density measurements); an
abnormal
absorption of dietary calcium; an abnormal increase or decrease in the
production and/or
release of messengers which affect serum calcium levels such as PTH and
calcitonin; and
an abnormal change in the response elicited by messengers which affect serum
calcium
levels.
Thus, calcium receptoi antagonists offer a unique approach towards the
pharmacotherapy of diseases associated with abnormal bone or mineral
homeostasis, such
as hypoparathyroidism, osteosarcoma, periodontal disease, fracture healing,
osteoarthritis,
rheumatoid arthritis, Paget's disease, humoral hypercalcemia associated with
malignancy
and fracture healing, and osteoporosis.
SUMMARY OF THE INVENTION
The present invention comprises novel calcium receptor antagonists represented
by
Formula (I) hereinbelow and their use as calcium receptor antagonists in the
treatment of a
variety of diseases associated with abnormal bone or mineral homeostasis,
including but
not limited to hypoparathyroidism, osteosarcoma, periodontal disease, fracture
healing,
osteoarthritis, rheumatoid arthritis, Paget's disease, humoral hypercalcemia
associated with
malignancy and fracture healing, and osteoporosis.
The present invention further provides a method for antagonizing calcium
receptors in an animal, including humans, which comprises administering to an
animal in
need thereof an effective amount of a compound of Formula (I), indicated
hereinbelow.
The present invention further provides a method for increasing serum
parathyroid
levels in an animal, including humans, which comprises administering to an
animal in need
thereof an effective amount of a compound of Formula (I), indicated
hereinbelow.
2
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
DETAILED DESCRIPTION OF THE INVENTION
The compounds of the present invention are selected from Formula (I)
hereinbelow:
R3 R4
Y2'N~G~A~B~RS
Y~ H
Y3 ~ R8
R7
Xs
Formula (I)
wherein:
YI is a covalent bond, alkylene or alkenylene of up to 4 carbon atoms,
unsubstituted or
substituted by C1_4 alkyl, or O;
Y2 is methylene, unsubstituted or substituted by C I _4 alkyl or haloalkyl;
Y3 is covalent bond or O, S, N-RIV or C I ~ alkylene-O, C 1 _4 alkylene-S, C j
_~ alkylene-
N-RIV;
R3 and R4 are, independently, methyl or ethyl, or, together, form cyclopropyl;
RS is aryl or fused aryl, dihydro or tetrahydro fused aryl, unsubstituted or
substituted with
any substituents being selected from the group consisting of OH, halogen, CI_4
alkyl, C1_4
alkoxy, C3_6 cycloalkyl, OS02RIV, CN, N02, OCF3, CF3, CH2CF3, (CH2)n C02RIV,
and O-(CH2)n C02RI~ , wherein n is an integer from 0 to 3 and RIV is selected
from the
group consisting of H, CI_4 alkyl, C3_6 cycloalkyl;
or RS is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O
or S, and is
aromatic, dihydro or tetrahydro, unsubstituted or substituted with any
substituents being
selected from the group consisting of OH, OCH3, CH(CH3)2, halogen, CI_4 alkyl,
CI-4
alkoxy, C3_6 cycloalkyl, OS02RIV, CN, N02, OCF3, CF3, CH2CF3, (CH2)n C02H,
(CH2)n C02RIV, and O-(CH2)n C02RIV;
G is a covalent bond, CHR6 or C-R6 ,wherein R6 is H, OH or O (forming a
ketone);
R~ is H, OH, or O-CI-4 alkyl;
Rg is H or C I _4 alkyl; or R7 and Rg together form a ketone;
3
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
A and B are, independently, selected from the group consisting of a bond, CH2,
NH, O, S"
and C=O, provided that either A or B is selected from CH2 and NH; or A and B
together
form a bond; or the A-B moiety is represented by CH=CH or C---C;
wherein
X 1 and XS are independently selected from the group consisting of H, halogen,
CN, N02,
Cl_q, alkyl, cycloalkyl, CH2-aryl, and CH2-heteroaryl; provided that either X1
or XS is H;
X2 , X3 and X4 are selected from the group consisting of H, halogen, O-C1_4
alkyl, O-aryl,
O-heteroaryl, CH2-aryl, CH2-heteroaryl, alkyl, C(O)aryl, C(O)heteroaryl,
CH(OH)aryl,
CH(OH)heteroaryl; and J-K;
J is a covalent bond, alkylene, O-alkylene or alkenylene of up to 5 carbon
atoms,
unsubstituted or substituted by a substituent selected from the group
consisting of C 1 _4
alkyl, OH, O{ forming a ketone), aryl, heteroaryl, and NR~t", wherein R' and
R" are
independently selected from the group consisting of H, alkyl, aryl,
heteroaryl, C(O)alkyl,
C(O)aryl, and C(O)heteroaryl;
I S K is selected from the group consisting of, C02RIV, OH, and CN;
and pharmaceutically acceptable salts and complexes thereof.
Preferably, the compounds of the present invention have a structure according
to
Formula (II):
R3 R4
~A~B~R5
~H H
~~H R6
~ xs
X2 ~ Xa
X3
Formula (II)
wherein:
R3 and R4 are, independently, methyl or ethyl, or, together, form cyclopropyl;
RS is aryl or fused aryl, or dihydro or tetrahydro fused aryl, unsubstituted
or substituted
with any substituents being selected from the group consisting of OH, halogen,
C 1 _4 alky l,
C 1 _4 alkoxy, C3_6 cycloalkyl, OS02RIV, CN, N02, OCF3, CF3, CH2CF3, wherein
RIV is
selected from the group consisting of H, C I _4 alkyl, C3_6 cycloalkyl, C3_6
cycloalkyl;
4
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
or RS is heteroaryl or fused heteroaryl; wherein the hetero-ring contains N, O
or S and is
aromatic, dihydro or tetrahydro, unsubstituted or substituted with any
substituents being
selected from the group consisting of OH, OCH3, CH(CH3}2, halogen, C 1 _4
alkyl, C 1 _4
alkoxy, C3_6 cycloalkyl, , CN, N02, OCF3, CF3, CH2CF3;
R6 is H, OH or O (forming a ketone); and
A and B are, independently, selected from the group consisting of a bond, CH2,
NH, O, S
and C=O, provided that either A or B is selected from CH2 and NH; or A and B
together
form a bond; or the A-B moiety is represented by CH=CH or C---C.
X1 and XS are independently selected from the group consisting of H, halogen,
CN, N02,
Cl_4 alkyl, cycloalkyl, CH2-aryl, and CH2-heteroaryl; provided that either X1
or XS is H;
X2, X3 and X4 are selected from the group consisting of H, halogen, O-Cl_4
alkyl, O-aryl,
O-heteroaryl, CH2-aryl, CH2-heteroaryl, alkyl, C(O)aryl, C(O)heteroaryl,
CH(OH)aryl, and
CH(OH)heteroaryl and J-K
J is a covalent bond, alkylene, O-alkylene or alkenylene of up to 5 carbon
atoms,
1 S unsubstituted or substituted by a substituent selected from the group
consisting of C I _4
alkyl, OH, O(ketone), aryl, heteroaryl, and NRR", wherein R' and R" are
independently
selected from the group consisting of H, alkyl, aryl, heteroaryl, C(O)alkyl,
C(O)aryl, and
C(O)heteroaryl;
K is selected from the group consisting of C02H, C02RlV, OH, and CN.
More preferably, RS is aryl or fused aryl or dihyro or tetrahydro aryl,
unsubstituted
or substituted with any substituents being selected from the group consisting
of OCH3,
CH2CH3, halogen, C3_6 heterocycloalkyl, CN, N02, OCF3, CF3, CH2CF3;or RS is
heteroaryl or fused heteroaryl, wherein the hetero-ring contains N, O or S and
is aromatic,
dihydro or tetrahydro, unsubstituted or substituted with any substituents
being selected
from the group consisting of OCH3, halogen, C 1 _4 alkyl, , CN, N02, OCF3,
CF3,
CH2CF3;
R6 is H; and
A and B are, independently, selected from the group consisting of a bond, CH2,
NH, O, S
and C=O, provided that either A or B is selected from CH2 and NH, or A and B
together
form a bond.
X I and Xg are selected from the group consisting of CI, F, CN, and N02;
provided that either Xl or Xg is H;
5
CA 02327279 2000-10-03
PCT/US99/07722
WO 99151569
X2, X3 and X4 is selected from the group consisting of H,F, CI, CN, O-aryl, O-
heteroaryl,
CH2-aryl, CH2-heteroaryl, C(O)aryt, C(O)heteroaryl, CH(OH)aryl,
CH(OH)heteroaryl or
J-K
J is a covalent bond, alkylene, alkenylene or O alkylene of up to 5 carbon
atoms,
unsubstituted or substituted by C1_4 alkyl, aryl, heteroaryl, or NR'R",
wherein R' and R"
are independently selected from the group consisting of H, alkyl, aryl,
heteroaryl,
C(O)alkyl, C(O)aryl, and C(O)heteroaryl;
K is C02RIV;
Most preferably, R5 is phenyl, naphthyl, heteroaryl or fused heteroaryl,
wherein the
heteroring contains N, O or S, and is aromatic, dihydro or tetrahydro;
unsubstituted or
substituted with any substituents being selected from the group consisting of
halogen,
OCH3, CF3, and C1-4alkyl;
R6 is H; and
A and B are, independently, selected from the group consisting of a bond, CH2,
O, or A and
B together form a bond.
X1 and X5 are independently Cl, CN, or N02;
provided that either X1 or X5 is H;
X2 or X3 or X4 are H, CN, Cl or J-K;
J is a covalent bond, alkylene or alkenylene of up to 5 carbon atoms,
unsubstituted or
substituted by aryl, heteroaryl, or NR'R", wherein R'and R" are selected from
the group
consisting of H, alkyl, aryl, heteroaryl, C(O)alkyl, C(O)aryl, and
C(O)heteroaryl;
K is C02RIV
Preferred heteroaryls useful in the present invention include unsubstituted
and
substituted quinolines, isoquinolines, benzofurans, dihydrobenzofurans,
benzothiophenes,
dihydrobenzothiophenes and pyridines.
As used herein "cycloalkyl" refers to optionally substituted 3-7 membered
carbocyclic rings wherein any substituents are selected from the group
consisting of, F, Cl,
Br, I, N(RlV)2, SRIV and O Rlv unless otherwise indicated.
As used herein "heterocycloalkyl" refers to optionally substituted 4, 5, 6 or
7
membered heterocyclic rings containing 1 to 2 heteroatoms selected from N, O,
and S.
As used herein, "aryl" refers to an optionally substituted aromatic group with
at
least one ring having a conjugated pi-electron system, containing up to two
conjugated or
fused ring systems. Aryl includes carbocyclic aryl, and biaryl groups, all of
which may be
6
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
optionally substituted. Preferred aryl include phenyl and naphthyl. More
preferred aryl '
include phenyl. Preferred substituents are selected from the group consisting
of halogen,
Cl_4 alkyl, OCF3~ CF3~ OMe, CN, OS02 R and N02~ wherein R represents Cl_4
alkyl or
C3_6 cycloalkyl.
As used herein, "acyl" refers to C 1_4 alkylcarbonyl.
As used herein, "alkenyl" refers to an optionally substituted hydrocarbon
group
containing at least one carbon-carbon double bond and containing upto 5 carbon
atoms
joined together. The alkenyl hydrocarbon chain may be straight, branched or
cyclic. Any
substituents are selected from the group consisting of halogen, C1_4 alkyl,
OCF3~ CF3,
OMe, CN, OS02 R and N02, wherein R represents C1_4 alkyl or C3_6 cycloalkyl.
As used herein, "alkynyl" refers to an optionally substituted hydrocarbon
group
containing at least one carbon-carbon triple bond between the carbon atoms and
containing
up to 5 carbon atoms joined together. The alkynyl hydrocarbon group may be
straight-
chained, branched or cyclic. Any substituents are selected from the group
consisting of
halogen, C I _4 alkyl, OCF3, CF3, OMe, CN, OS02 R and N02, wherein R
represents C I _4
alkyl or C3_6 cycloalkyl.
The compounds of the present invention may contain one or more asymmetric
carbon atoms and may exist in racemic and optically active forms. All of these
compounds
and diastereomers are contemplated to be within the scope of the present
invention.
Preferred compounds of the present inventions include:
(R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carboethoxyethyl)phenoxy)propyl]-I, I-
dimethyl-2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carboxyethyl)phenoxy)propyl]-1, I-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carbethoxypropyl)phenoxy)propyl]-1,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carboxypropyl)phenoxy)propyl]-l, l-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(2-carbethoxyethyl)phenoxy)propylJ-1, I-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(2-carboxyethyl)phenoxy)propyl ]- I ,1-dimethyl-
2-(2-
naphthyl)ethylamine;
7
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(R)-N-(2-Hydroxy-3-(2-cyano-4-(3-carbethoxypropyl)phenoxy)propyl]-1,1-dimethyl-
2-(2=
naphthyl)ethylamine;
(R)-N-(2-Hydroxy-3-(2-cyano-4-(3-carboxypropyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(3-carbethoxypropyl)phenoxy)propyl]-1, I-
dimethyl-2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(3-carboxypropyl}phenoxy)propyl]- l , l -
dimethyl-2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(2-carbethoxyethyl)phenoxy)propyl]-1,1-dimethyl-
2-(2-
naphthyl)ethylamine;
{R)-N-[2-Hydroxy-3-(2-cyano-3-(2-carboxyethyl}phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(carbethoxymethyl)phenoxy)propyl]-I, I-dimethyl-
2-(2-
naphthyl)ethylamine;
IS (R)-N-[2-Hydroxy-3-(2-cyano-4-(carboxymethyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(carbethoxymethyl)phenoxy)propyl]-I, I-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(carboxymethyl)phenoxy)propyl]-1,1-dimethyl-2-(2-
naphthyl)ethylamine;
R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carbethoxy-traps-ethylene)phenoxy)propyl]-1, I-
dimethyl-2-(2-naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-{2-cyano-4-(2-carboxy-traps-ethylene)phenoxy)propyl]-1,1-
dimethyl-
2-(2-naphthyl)ethylamine;
(R)-I-[1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3(4-(2-phenyl-2-R,S-
methoxycarbonylethy!))phenoxy]-propan-2-ol;
(R)-1-[ l,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-((4-(2-phenyl-2-R,S-
carboxyethyl))phenoxy]-propan-2-ol;
{R)-I-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(3-benzyl-4-
methoxycarbonylmethyl)phenoxy]-propan-2-ol;
(R)-I-[ 1,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-benzyl-4-
methoxycarbonylmethyl)phenoxy]-propan-2-ol;
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(R)-1-[ 1,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-benzyl-4-
carboxymethyl)phenoxyr
propan-2-ol;
(R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl}ethylamino]-3-[(3-benzyl-4-
carboxymethyl)phenoxy]-propan-2-ol;
(R)-1-[1,1-dimethyl-2-{4-methoxyphenyl)ethylamino]-3-[(4-(3-
hydroxy)propyl)phenoxy]-
propan-2-ol;
(R)-1-[ l,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-((4-(2-
hydroxy)ethyl)phenoxy]-
propan-2-ol;
(R)-1-[ 1,1-dimethyl-2(4-methoxyphenyl)ethylamino]-3-[(4-(2-
cyano)ethyl)phenoxy]-
propan-2-ol;
(R)-Methyl 2-[4-[3-[2-(4-methoxyphenyl)-1,1-dimethylethylamino]-2-
hydroxypropoxy]benzoylbenzoate;
(R)-2-[4-[3-[2-(4-Methoxyphenyl)-l, l-dimethylethylamino]-2-
hydroxypropoxy]benzoylbenzoic acid;
(R)-1-[1,I-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(4-cyanomethyl)phenoxy]-
propan-2-ol;
(R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(4-cyano)phenoxy]-
propan-2-ol;
{R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(4-
methoxycarbonylmethyl)phenoxy)-propan-2-ol;
(R)-1-[1,1-dimethyl-2-(4-methoxyphenylethylamino]-3-[(2-nitro-4-cyano)phenoxy]-
propan-2-ol;
(R)-I-[ l,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-vitro-4-
(hydroxymethyl))phenoxy]-propan-2-ol;
(R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-vitro-4-
methoxycarbonylmethyl)phenoxy]-propan-2-ol;
(R)-I-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-vitro-4-
carboxymethyl)phenoxy]-propan-2-ol;
(R)-I-[ 1,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(4-methoxycarbonyl)phenoxy]-
propan-
2-0l;
(R)-1-[1,I-dimethyl-2-(2-naphthyl)ethylamino]-3-[(4-carboxy)phenoxy]-propan-2-
ol;
(R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-cyano-4-
ethoxycarbonylmethyl)phenoxy]-propan-2-ol;
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-cyano-4-
carboxymethyl)phenoxy]-propan-2-ol;
(R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(4-
methoxycarbonylethyl)phenoxy]-propan-2-ol;
N-[2R-hydroxy-3-[[2-nitro-4-[2S-ethoxycarbonyl-2-
[methylsulfonyl]amino]phenoxy]propyl]-1,1-dimethyl-2-[4-
methoxyphenyl]ethylamine;
N-[2R-hydroxy-3-[[2-vitro-4-[2S-methoxycarbonyl-2-[phthalimido]phenoxy]propyl]-
1,1-
dimethyl-2-[naphthyl]ethylamine;
N-[2R-hydroxy-3-[[2-vitro-4-[2S-carboxy-2-[[[2-
carboxy]phenyl]carbonyl]amino]ethyl]phenoxy]propyl]-1,1-dimethyl-2-
[naphthyl]ethylamine;
N-[2R-hydroxy-3-[[2-vitro-4-[2S-methoxycarbonyl-2-[[[2-
carboxy]phenyl]carbonyl]amino] ethyl]phenoxy]propyl]-1,1-dimethyl-2-
[naphthyl]ethylamine;
(R)-1-[1,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-(2-aminophenoxy)-4-
methoxycarbonyl)phenoxy]-propan-2-ol;
(R)-1-[ 1,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-(2-aminophenoxy)-4-
carboxy)phenoxy]-propan-2-ol;
and pharmaceutically acceptable salts and complexes thereof.
More preferred compounds of the present invention include:
(R)-N-[2-Hydroxy-3-(2-cyano-4.-(2-carboethoxyethyl)phenaxy)propyl]-1,1-
dimethyl-2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carboxyethyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carbethoxypropyl)phenoxy)propyl]-1,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carboxypropyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R}-N-[2-Hydroxy-3-(2-cyano-5-(2-carbethoxyethyl)phenoxy)propyl]-1,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(2-carboxyethyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(R)-N-[2-Hydroxy-3-(2-cyano-4-(3-carbethoxypropyl)phenoxy)propyl]-1.1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(3-carboxypropyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(3-carbethoxypropyl)phenoxy)propyl]-1,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(3-carboxypropyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(2-carbethoxyethyl)phenoxy)propyl]-1,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(2-carboxyethyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(carbethoxymethyl)phenoxy)propyl]-I,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(carboxymethyl)phenoxy)propyl]-1,1-dimethyl-2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(carbethoxymethyl)phenoxy)propyl]- I, I-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(carboxymethyl)phenoxy)propyl]-1,1-dimethyl-2-(2-
naphthyl)ethylamine;
R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carbethoxy-traps-ethylene)phenoxy)propyl]-1,1-
dimethyl-2-(2-naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carboxy-traps-ethylene)phenoxy)propyl]-1,1-
dimethyl-
2-(2-naphthyl)ethylamine;
(R)-1-[1,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-(2-aminophenoxy)-4-
methoxycarbonyl)phenoxy]-propan-2-ol;
(R)-1-[ I,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3(4-(2-phenyl-2-R,S-
methoxycarbonylethyl))phenoxy]-propan-2-ol;
(R)-1-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(3-benzyl-4-
methoxycarbonylmethyl)phenoxy]-propan-2-ol;
(R)-1-[ 1,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-benzyl-4-
methoxycarbonylmethyl)phenoxy]-propan-2-ol;
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(R)-1-[ 1, I-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-benzyl-4-
carboxymethyl)phenoxy]=
propan-2-ol;
(R)-Methy I 2-[4-[3-[2-(4-methoxyphenyl)- I ,1-dimethylethylamino]-2-
hydroxypropoxy]benzoylbenzoate;
(R)-1-( 1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-cyano-4-
ethoxycarbonylmethyl)phenoxy]-propan-2-ol;
(R)-1-[ I,1-dimethyl-2-(4-methoxyphenyl)ethylamino)-3-[(2-vitro-4-
methoxycarbonylmethyl)phenoxy]-propan-2-ol;
(R)- I -[ I ,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(4-
methoxycarbonyl)phenoxy]-propan-
2-0l; N-[2R-hydroxy-3-[[2-vitro-4-[2S-ethoxycarbonyl-2-
[methylsulfonyl]aminojphenoxy]propyl]-1,1-dimethyl-2-[4-
methoxyphenyl]ethylamine;
N-[2R-hydroxy-3-[[2-vitro-4-[2S-methoxycarbonyl-2-[phthalimido]phenoxy]propyl]-
I, I-
dimethyl-2-[naphthyl]ethylamine;
N-[2R-hydroxy-3-[[2-vitro-4-[2S-methoxycarbonyl-2-[[[2-
carboxy]phenyl]carbonyl]amino] ethyl]phenoxy]propyl]-1,1-dimethyl-2-
[naphthyl]ethylamine; and
pharmaceutically acceptable salts and complexes thereof.
The most preferred compounds useful in the present invention include:
(R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carboethoxyethyl)phenoxy)propyl]-I,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carboxyethyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carbethoxypropyl)phenoxy)propyl]- I ,1-
dimethyl-2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carboxypropyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(2-carbethoxyethyl)phenoxy)propyl]-1,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(2-carboxyethyl)phenoxy)propyl)-1, I-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-(2-Hydroxy-3-(2-cyano-4-(3-carbethoxypropyl)phenoxy)propyl]- l , l -
dimethyl-2-(2-
naphthyl)ethylamine;
12
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(R)-N-[2-Hydroxy-3-(2-cyano-4-(3-carboxypropyl)phenoxy)propyl)-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(3-carbethoxypropy 1)phenoxy)propyl]- I ,1-
dimethyl-2-(2-
naphthyl)ethylamine;
(R)-N-(2-Hydroxy-3-(2-cyano-3-(3-carboxypropyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(2-carbethoxyethyl)phenoxy)propyl]-I,1-dimethyl-
2-(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-3-(2-carboxyethyl)phenoxy}propyl]-l, l-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(carbethoxymethyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(carboxymethyl)phenoxy)propyl]-I, I-dimethyl-2-
(2-
naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(carbethoxymethyl)phenoxy)propyl]-1,1-dimethyl-2-
(2-
naphthyl}ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-5-(carboxymethyl)phenoxy)propyl]-1,1-dimethyl-2-(2-
naphthyl)ethylamine;
R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carbethoxy-traps-ethylene}phenoxy)propyl]-l, I-
dimethyl-2-(2-naphthyl)ethylamine;
(R)-N-[2-Hydroxy-3-(2-cyano-4-(2-carboxy-traps-ethylene)phenoxy}propyl]-1,1-
dimethyl-
2-(2-naphthyl)ethylamine;
(R)-1-[ I,1-dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-(2-aminophenoxy)-4-
methoxycarbonyl)phenoxy]-propan-2-ol; and
and pharmaceutically acceptable salts and complexes thereof.
Pharmaceutically acceptable salts are non-toxic salts in the amounts and
concentrations at which they are administered.
Pharmaceutically acceptable salts include acid addition salts such as those
containing sulfate, hydrochloride, fumarate, maleate, phosphate, sulfamate,
acetate, citrate,
lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-
toluenesulfonate,
cyclohexylsulfamate and quinate. A preferred salt is a hydrochloride.
Pharmaceutically
acceptable salts can be obtained from acids such as hydrochloric acid, malefic
acid, sulfuric
acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid,
tartaric acid,
13
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid,
p-
toluenesulfonic acid, cyclohexylsulfamic acid, fumaric acid, and quinic acid.
Pharmaceutically acceptable salts also include basic addition salts such as
those
containing benzathine, chloroprocaine, choline, diethanolamine,
ethylenediamine,
meglumine, procaine, aluminum, calcium, lithium, magnesium, potassium, sodium,
ammonium, alkylamine, and zinc, when acidic functional groups, such as
carboxylic acid or
phenol are present.
The present invention provides compounds of Formula (I) above which can be
prepared using standard techniques. An overall strategy for preparing
preferred compounds
described herein can be carried out as described in this section. The examples
which follow
illustrate the synthesis of specific compounds. Using the protocols described
herein as a
model, one of ordinary skill in the art can readily produce other compounds of
the present
tnventton.
All reagents and solvents were obtained from commercial vendors. Starting
materials (e.g., amines and epoxides) were synthesized using standard
techniques and
procedures.
Scheme 1
R4
R3~A~ ,RS
N
as ~
OH O O ro~ ~~ ,AS p' 'OH H R6
H /~ a
X~ ~ Xs ws-o~o X~ ~ Xs ~ as X, ~ Xs
K CO acetone I ~ EtOH ~ I
X X~ 2 Heat X~ X~ Heat Xi / X~
Xs X
14
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Scheme 2
O PhenyIMgBr HO / \ / \
_O I \ Ether, THF -O I ~ p-tolueneS03H
i
/ \ / \
1. Os04, Cr03, HZS04 -O I ~ O H2 Pd/~ -O
i i
HO O
HO O
/ \
1. Me3PhSi, 12 HO
2. H~SO" MeOH ; I
i
O O
Scheme 3
NO H NO COOMe
2F ~ COOMe
w ~ KzC03, DMF w w
I ~ + ~o ~ '--.
Heat
,O
H2, Pd/C
COOMe
COOMe NHz
NH2 EtSH, AICI3 ( w O I w
I
CHZCI2
OH ,O
IS
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Scheme 4
A~c off
i . cr~o, sr,a4 ~o ~ N~co3 (a~ N ~
_._ p -
2. N~oH
i
COOEt COOEt
O~O
~/i
COa N I w
NosO~p w w
NHZ
p COOEt
Scheme 5
F
\ O OH
\ i.KOt-Bu, THF N ~ I.LiOH, THF, hlz0, D N y
\ ~ \ 2.(Imidazole)2C--0, EtOH \ \
2. B _.~ I / 3. cc HCI, CH3CN
Br PdCl2(dppf)
CsC03, O
0 ,.i0
O 9-BBN, THF
O
~O B~
O
B
I
16
SUBSTITUTE SHEET (RULE 26)
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Scheme 6
l.Tf20, pyr, DCM OH
i 2. Zn(CN)2, DMF, a N
HO ~ ~~~
3_ NaCN, DMSO, a ~
~ i
i
~
~O ~.O
O O
Scheme 7
OH 1. Br2. CHCI3 N,
2, CuCN, N-Mepyrrolidone, D i
\ ~ O
O O
Scheme 8
F
N ~ O OH
\ t.KOt-8u, THF N~~ I.LiOH, THF, HzO, v N
\ 2.(Imidazole)2C=O, EtOH
2. B (from Scheme 8)
I PdCIZ(dppf) / 3. cC. HCI, CHaCN
U w
CsC03, O ~ O
:r
O'. ._ ''Ow
17
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Scheme 9
N\~ ~H O ~ N OH
\ O \\ .\
il
_~ y
' Pd(OAc)2, MeCN, H20, 1G1C03
Br
O~O
i
General Preparation
A general procedure used to synthesize many of the compounds can be carried
out
as described in Scheme 1: a solution of aryl alcohol in acetone was treated
with an
appropriate base such as K2C03, heated for 15 min. R-glycidyl nosylate was
added and the
reaction continued overnight to give the corresponding glycidyl ether. In the
case of an
alkyl alcohol (e.g., Y3 is CIA alkylene-O), a stronger base, e.g. NaH in DMF
was used.
This method can also be used for aryl alcohols. A solution of the substituted
glycidyl ether
and excess amine (typically 1,1-dimethyl-2-(4-methyloxyphenyl)ethylamine) in
absolute
ethanol, acetonitrile, THF or any other similar solvent in the presence of a
suitable catalyst
such as LiCIOq, is stirred overnight at reflux. The product is purified by
normal phase
chromatography. Hydrochloride salts are prepared by treatment of the
corresponding free
base with HCI either in gas phase or 4M dioxane solution, or any other
standard method. A
method for preparing methyl 2-(2-benzyl-4-hydroxy)phenylacetates is outlined
in Scheme
2. Grignard addition followed by dehydration and oxidative cleavage of the
resulting
double bond yields the benzophenone derivative which is deoxygenated and
demethylated
to give the aryl alcohol acid and its corresponding ester. A method for
preparing 1-(2-
aminophenoxy)-2-methoxycarbonyl-5-hydroxy-benzenes is outlined in Scheme 3.
Displacement of the aryl fluoride gave the biphenyl ether. Reduction of the
vitro group
followed by cleavage of the methyl ether gave the desired aryl alcohol.
18
CA 02327279 2000-10-03
WO 99/51569 PCTNS99/07722
Schemes 4-9 outlines the general synthesis of the corresponding phenol
substituted with'
the different propionic and butiric acid/esters side chains, with appropriate
manipulation
and protection of any chemical functionality, synthesis of the remaining
compounds of
Formula (I) is accomplished by methods analogous to those above and to those
described in
the Experimental section.
In order to use a compound of Formula (I) or a pharmaceutically acceptable
salt
thereof for the treatment of humans and other mammals, it is normally
formulated in
accordance with standard pharmaceutical practice as a pharmaceutical
composition.
The calcilytic compounds can be administered by different routes including
intravenous, intraperitoneal, subcutaneous, intramuscular, oral, topical
(transdermal), or
transmucosal administration. For systemic administration, oral administration
is preferred.
For oral administration, for example, the compounds can be formulated into
conventional
oral dosage forms such as capsules, tablets, and liquid preparations such as
syrups, elixirs,
and concentrated drops.
Alternatively, injection (parenteral administration) may be used, e.g.,
intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection,
the
compounds of the invention are formulated in liquid solutions, preferably, in
physiologically compatible buffers or solutions, such as saline solution,
Hank's solution, or
Ringer's solution. In addition, the compounds may be formulated in solid form
and
redissolved or suspended immediately prior to use. Lyophilized forms can also
be
produced.
Systemic administration can also be by transmucosal or transdermal means. For
transmucosal or transdermal administration, penetrants appropriate to the
barrier to be
permeated are used in the formulation. Such penetrants are generally known in
the art, and
include, for example, for transmucosal administration, bile salts and fusidic
acid
derivatives. In addition, detergents may be used to facilitate permeation.
Transmucosal
administration, for example, may be through nasal sprays, rectal
suppositories, or vaginal
suppositories.
For topical administration, the compounds of the invention can be formulated
into
ointments, salves, gels, or creams, as is generally known in the art.
The amounts of various calcilytic compounds to be administered can be
determined
by standard procedures taking into account factors such as the compound IC50,
EC50, the
biological half-life of the compound, the age, size and weight of the patient,
and the disease
19
CA 02327279 2000-10-03
WO 99/51569 PCTNS99107722
or disorder associated with the patient. The importance of these and other
factors to be
considered are known to those of ordinary skill in the art.
Amounts administered also depend on the routes of administration and the
degree
of oral bioavailabitity. For example, for compounds with low oral
bioavailability,
relatively higher doses will have to be administered.
Preferably the composition is in unit dosage form. For oral application, for
example, a tablet, or capsule may be administered, for nasal application, a
metered aerosol
dose may be administered, for transdermal application, a topical formulation
or patch may
be administered and for transmucosal delivery, a buccal patch may be
administered. In
each case, dosing is such that the patient may administer a single dose.
Each dosage unit for oral administration contains suitably from 0.01 to 500
mg/Kg,
and preferably from 0.1 to 50 mg/Kg, of a compound of Formula (I) or a
pharmaceutically
acceptable salt thereof, calculated as the free base. The daily dosage for
parenteral, nasal,
oral inhalation, transmucosal or transdermal routes contains suitably from
0.01 mg to 100
I S mg/Kg, of a compound of Formula(I). A topical formulation contains
suitably 0.01 to 5.0%
of a compound of Formula (I). The active ingredient may be administered, for
example,
from 1 to 6 times per day, preferably once, sufficient to exhibit the desired
activity, as is
readily apparent to one skilled in the art.
As used herein, "treatment" of a disease includes, but is not limited to
prevention,
retardation and prophylaxis of the disease.
Diseases and disorders which might be treated or prevented, based upon the
affected cells, include bone and mineral-related diseases or disorders;
hypoparathyroidism;
those of the central nervous system such as seizures, stroke, head trauma,
spinal cord
injury, hypoxia-induced nerve cell damage, such as occurs in cardiac arrest or
neonatal
distress, epilepsy, neurodegenerative diseases such as Alzheimer's disease,
Huntington's
disease and Parkinson's disease, dementia, muscle tension, depression,
anxiety, panic
disorder, obsessive-compulsive disorder, post-traumatic stress disorder,
schizophrenia,
neuroleptic malignant syndrome, and Tourette's syndrome; diseases involving
excess water
reabsorption by the kidney, such as syndrome of inappropriate ADH secretion
(SIADH),
cirrhosis, congestive heart failure, and nephrosis; hypertension; preventing
and/or
decreasing renal toxicity from cationic antibiotics (e.g., aminoglycoside
antibiotics); gut
motility disorders such as diarrhea and spastic colon; GI ulcer diseases; GI
diseases with
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
excessive calcium absorption such as sarcoidosis; autoimmune diseases and
organ
transplant rejection; squamous cell carcinoma; and pancreatitis.
In a preferred embodiment of the present invention, the present compounds are
used to increase serum parathyroid hormone ("PTH") levels. Increasing serum
PTH levels
can be helpful in treating diseases such as hypoparathyroidism, osteosarcoma,
periodontal
disease, fracture, osteoarthritis, rheumatoid arthritis, Paget's disease,
humoral
hypercalcemia malignancy and osteoporosis.
Another aspect of the present invention describes a method of treating a
patient
comprising administering to the patient an amount of a present compound
sufficient to
increase the serum PTH level. Preferably, the method is carried out by
administering an
amount of the compound effective to cause an increase in duration and/or
quantity of serum
PTH level sufficient to have a therapeutic effect.
In various embodiments , the compound administered to a patient causes an
increase in serum PTH having a duration of up to one hour, about one to about
twenty-four
IS hours, about one to about twelve hours, about one to about six hours, about
one to about
five hours, about one to about four hours, about two to about five hours,
about two to about
four hours, or about three to about six hours.
In an alternattive embodimenf of the present invention, the compound
administered
to a patient causes an increase in serum PTH having a duration of more than
about twenty
four hours provided that it is co-administered with an anti resorptive agent.
In additional different embodiments, the compound administered to a patient
causes an increase in serum PTH of up to two fold, two to five fold, five to
ten fold, and at
least 10 fold, greater than peak serum PTH in the patient. The peak serum
level is
measured with respect to a patient not undergoing treatment.
Composition of Formula (I) and their pharmaceutically acceptable salts which
are
active when given orally can be formulated as syrups, tablets, capsules and
lozenges. A
syrup formulation will generally consist of a suspension or solution of the
compound or salt
in a liquid carrier for example, ethanol, peanut oil. olive oil, glycerine or
water with a
flavoring or coloring agent. Where the composition is in the form of a tablet,
any
pharmaceutical carrier routinely used for preparing solid formulations may be
used.
Examples of such carriers include magnesium stearate, terra albs, talc,
gelatin, acacia,
stearic acid, starch, lactose and sucrose. Where the composition is in the
form of a capsule,
any routine encapsulation is suitable, for example using the aforementioned
carriers in a
21
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
hard gelatin capsule shell. Where the composition is in the form of a soft
gelatin shell
capsule any pharmaceutical carrier routinely used for preparing dispersions or
suspensions
may be considered, for example aqueous gums, celluloses, silicates or oils,
and are
incorporated in a soft gelatin capsule shell.
S Typical parenteral compositions consist of a solution or suspension of a
compound
or salt in a sterile aqueous or non-aqueous carrier optionally containing a
parenterally
acceptable oil, for example polyethylene glycol, polyvinylpyrrolidone,
lecithin, arachis oil
or sesame oil.
Typical compositions for inhalation are in the form of a solution, suspension
or
emulsion that may be administered as a dry powder or in the form of an aerosol
using a
conventional propellant such as dichlorodifluoromethane or
trichlorofluoromethane.
A typical suppository formulation comprises a compound of Formula (I) or a
pharmaceutically acceptable salt thereof which is active when administered in
this way,
with a binding and/or lubricating agent, for example polymeric glycols,
gelatins, cocoa-
butter or other low melting vegetable waxes or fats or their synthetic
analogs.
Typical dermal and transdermal formulations comprise a conventional aqueous or
non-aqueous vehicle, for example a cream, ointment, lotion or paste or are in
the form of a
medicated plaster, patch or membrane.
Preferably the composition is in unit dosage form, for example a tablet,
capsule or
metered aerosol dose, so that the patient may administer a single dose.
No unacceptable toxological effects are expected when compounds of the present
invention are administered in accordance with the present invention.
The biological activity of the compounds of Formula (I) are demonstrated by
the
following tests:
f I) Calcium Receptor Inhibitor Assax
Calcilytic activity was measured by determining the ICgO of the test compound
for
blocking increases of intracellular Ca2+ elicited by extracellular Ca2+ in HEK
293 4.0-7
cells stably expressing the human calcium receptor. HEK 293 4.0-7 cells were
constructed
as described by Rogers et al., J. Bone Miner. Res. 10 Suppl. 1:S483, 1995
(hereby
incorporated by reference herein). Intracellular Ca2+ increases were elicited
by increasing
extracellular Ca2+ from 1 to 1.75 mM. Intracellular Ca2+ was measured using
fluo-3, a
fluorescent calcium indicator.
22
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
The procedure was as follows:
1. Cells were maintained in T-150 flasks in selection media (DMEM supplemented
with 10% fetal bovine serum and 200 ug/mL hygromycin B), under 5% C02:95% air
at
37 oC and were grown up to 90% confluency.
2. The medium was decanted and the cell monolayer was washed twice with
phosphate-buffered saline (PBS) kept at 37 oC. After the second wash, 6 mL of
0.02%
EDTA in PBS was added and incubated for 4 minutes at 37 oC. Following the
incubation,
cells were dispersed by gentle agitation.
3. Cells from 2 or 3 flasks were pooled and pelleted ( 100 x g). The cellular
pellet
was resuspended in 10-15 mL of SPF-PCB+ and pelleted again by centrifugation.
This
washing was done twice.
Sulfate- and phosphate-free parathyroid cell buffer (SPF-PCB) contains 20 mM
Na-Hepes, pH 7.4, 126 mM NaCI, 5 mM KCI, and 1 mM MgCl2. SPF-PCB was made up
and stored at 4 oC. On the day of use, SPF-PCB was supplemented with 1 mg/mL
of
D-glucose and 1 mM CaCl2 and then split into two fractions. To one fraction,
bovine
serum albumin (BSA; fraction V, ICN) was added at 5 mg/mL (SPF-PCB+). This
buffer
was used for washing, loading and maintaining the cells. The BSA-free fraction
was used
for diluting the cells in the cuvette for measurements of fluorescence.
4. The pellet was resuspended in 10 mL of SPF-PCB+ containing 2.2 uM fluo-3
(Molecular Probes) and incubated at room temperature for 35 minutes.
5. Following the incubation period, the cells were pelleted by centrifugation.
The
resulting pellet was washed with SPF-PCB+. After this washing, cells were
resuspended in
SPF-PCB+ at a density of 1-2 x 106 celEs/mL.
6. For recording fluorescent signals, 300 uL of cell suspension were diluted
in 1.2
mL of SPF buffer containing 1 mM CaCl2 and 1 mg/mL of D-glucose. Measurements
of
fluorescence were performed at 37 oC with constant stirring using a
spectrofluorimeter.
Excitation and emission wavelengths were measured at 485 and 535 nm,
respectively. To
calibrate fluorescence signals, digitonin (5 mg/mL in ethanol) was added to
obtain Fmax,
and the apparent Fmin was determined by adding Tris-EGTA (2.5 M Tris-Base, 0.3
M
EGTA). The concentration of intracellular calcium was calculated using the
following
equation:
Intracellular calcium = (F-Fmin/Fmax) x Kd~ where Kd = 400 nM.
23
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
7. To determine the potential calcilytic activity of test compounds, cells
were
incubated with test compound (or vehicle as a control) for 90 seconds before
increasing the
concentration of extracellular Ca2+ from 1 to 2mM. Calcilytic compounds were
detected
by their ability to block, in a concentration-dependent manner, increases in
the
concentration of intracellular Ca2+ elicited by extracellular Ca2+
In general, those compounds having lower IC50 values in the Calcium Receptor
Inhibitor Assay are more preferred compounds. Compounds having an IC50 greater
than
50 uM were considered to be inactive. Preferred compounds are those having an
IC50 of
lOuM or lower, more preferred compounds have an ICgO of luM, and most
preferred
compounds have an IC50 of 0.1 uM or lower.
(II) Calcium Receptor Bindin_gy Assay
HEK 293 4.0-7 cells stably transfected with the Humait Parathyroid Calcium
Receptor("HuPCaR") were scaled up in T180 tissue culture flasks. Plasma
membrane is
obtained by polytron homogenization or glass douncing in buffer (SOmM Tris-HCl
pH 7.4,
1mM EDTA, 3mM MgCl2) in the presence of a protease inhibitor cocktail
containing IuM
Leupeptin, 0.04 uM Pepstatin, and 1 mM PMSF. Aliquoted membrane was snap
frozen and stored at -80oC. 3H labeled compound was radiolabeled to a
radiospecific
activity of 44Ci/mmole and was aliquoted and stored in liquid nitrogen for
radiochemical
stability.
A typical reaction mixture contains 2 nM 3H compound ((R,R)-N-4'-Methoxy-t-3-
3'-methyl-1'-ethylphenyl-1-(1-naphthyl)ethylamine), or 3H compound (R)-N-[2-
Hydroxy-
3-(3-chloro-2-cyanophenoxy)propylJ-I,1-dimethyl-2-(4-methoxyphenyl)ethylamine
4-10
ug membrane in homogenization buffer containing 0.1 % gelatin and 10% EtOH in
a
reaction volume of 0.5 mL. Incubation is performed in 12 x 75 polyethylene
tubes in an ice
water bath. To each tube 25 uL of test sample in 100% EtOH is added, followed
by 400 uL
of cold incubation buffer, and 25 uL of 40 nM 3H-compound in I00% EtOH for a
final
concentration of 2nM. The binding reaction is initiated by the addition of 50
uL of 80-200
ug/mL HEK 293 4.0-7 membrane diluted in incubation buffer, and allowed to
incubate at
4oC for 30 min. Wash buffer is 50 mM Tris-HCI containing 0.1 % PEI.
Nonspecific
binding is determined by the addition of 100-fold excess of unlabeled
homologous ligand,
and is generally 20% of total binding. The binding reaction is terminated by
rapid filtration
onto 1 % PEI pretreated GFIC filters using a Brandel Harvestor. Filters are
placed in
scintillation fluid and radioactivity assessed by liquid scintillation
counting.
24
CA 02327279 2000-10-03
WO 99/51569 PCTIUS99/07722
The following examples are illustrative, but not limiting of the embodiments
of the
present invention.
Example 1
Preparation of (R)-1-f 1,1-dimethvl-2-(4-methoxyphe~l)ethylaminol-3y4-(2
phenyl-2-R S
methox~rcarbonylethyl)lphenoxyl-propan-2-of hydrochloride salt
a) (R) 4-(2-Phenyl-2-R,S-(methoxycarbonyl)ethyl)-phenoxyglycidol
The material purchased from Sigma, 3-(p-hydroxyphenyl) 2-phenylpropionic acid,
( I g, 4.1
mmol) was dissolved in methanol (10 mL) and was treated with concentrated
H2S04 (0.5
mL) at reflux for 16 h. The mixture was cooled, evaporated, taken up in 5%
NaHC03 and
extracted into diethyl ether. A mixture of this crude compound (1 g, 4.1
mmol), K2C03
(0.62 g, 4.5 mmol), and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (1.6 g, 6.2
mmol) in
acetone (50 mL) was refluxed for 24 h. The mixture was cooled, concentrated,
taken up in
H20, extracted with EtOAc. The organic extracts were washed with 5% NaHC03,
brine,
dried over MgS04, filtered, concentrated and purified by flash column
chromatography (50
% EtOAc/Hexane) to afford the title compound ( 1 g, 75%) as an off white foam.
1 H-NMR
(250 MHz, CDCl3): b 2.70-2.73 (m, 1H), 2.85-2.99 (m, 2H), 3.29-3.35 (m, 2H),
3.38 (s ,
3H), 3.76-3.90 (m, 2H), 4.15 (dd, j=5.4, 1 I.4 Hz, 1H), 6.78 (d, J=9.1 Hz,
2H), 7.01 (d,
J=9.3 Hz, 2H), 7.23-7.29 (m, SH).
b} (R) I-[ 1,1-dimethyl-2-(4-methoxyphenyl)ethylaminoJ-3(4-(2-phenyl-2-R,S-
methoxycarbonylethyl))phenoxy]-propan-2-of hydrochloride salt
A mixture of the compound of Example 1(a) (0.3 g, 0.96 mmol), and 4-
methoxyphenyl-
1, I-dimethyl ethylamine (0.2 g, I.06 mmol) in ethanol (20 mL) was heated at
reflux for 24
h. The mixture was cooled, concentrated and purified by flash column
chromatography
(3% MeOH/ CHC13) to afford as a colorless oil (0.321 g, 69%) which (0.200 g)
was stirred
in methanol and added 4M HCI, concentrated and triturated in ether to give the
title
compound (0.325 g). ESMS (M+H)+ m/e 492.4.
25
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Example 2
Preparation of (R)-I-f 1.I-dimethvl-2-(4-methoxyphenyl)ethylaminol-3-f(4-(2-
phenyl-2-
R.S-carboxyeth~phenoxyl-propan-2-of ~drochloride salt
The remaining material from Example 1 (b} (0.13 g, 0.28 mmol) was dissolved in
methanol (5 mL) and was treated with IM NaOH aq (1.2 mL) at room temperature
for 16 h.
The reaction was quenched with IM HCI, extracted with CHCI3, dried with MgS04,
filtered and evaporated to afford a white powder (0.12 g). ESMS (M+H)+ m/e;
478.4.
Example 3
Preparation of (R)-1-f 1.I-dimethyl-2-l4-methoxyphenyl)ethylaminol-3-f(3
benzyl 4
methoxvcarbonvlmethyl)phenox3rl-pronan-2-of hydrochloride salt
a) 2-Benzyl-4-methoxyphenylacetic acid
A solution of 2-benzoyl-4-methoxyphenylacetic acid (5.18 g, 20.3 mmol),
prepared by the
method of J. Med. Chem. 19$1, 24, 998, in glacial acetic acid (200 mL) was
treated under
argon with 10% Pd/C ( 1 g) and hydrogenated at 50 psi for 17 h. The mixture
was filtered
using celite and the filtrate concentrated and chased with toluene and
methylene chloride to
give the title compound (4.3 g). 1H-NMR (350 MHz, CDC13): b 3.52 (s, 2H), 3.75
(s, 3H),
4.0 (s, 2H), 6.7 (m, 2H). 7.15 (m, 6H).
b) Methyl2-(2-benzyl-4-hydroxy)phenylacetate
A mixture of the compound of Example 3 (a) (0.50 g, 1.9 mmol), PhSiMe3 (5 mL),
and
iodine (0.99 g, 7.8 mmol) was heated at 130 oC for 16 h. The mixture was
cooled, added
saturated NaHS03 aq and extracted with EtOAc. The organic extracts were washed
with
H20, brine, dried over MgS04, filtered concentrated, dissolved in methanol (
10 mL) and
treated with concentrated sulfuric acid ( I mL) at reflux for 16 h. The
material was
evaporated, quenched with NaHC03 and extracted with ether to give the title
compound
(0.673 g). I H-NMR (250 MHz, CDC13): 8 3.52 (s, 2H), 3.59 (s, 3H), 3.94 (s,
2H) 6.56-
7.25 (m, 8H).
26
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
c) {R)-Methyl 2-(2-benzyl-4-glycidyl)phenylacetate
A mixture of the compound of Example 3 (b) ( 2 mmol), K2C03 (0.39 g, 2.8
mmol), and 2 R- (-)-glycicyl -3-nitrobenzenesulfonate (0.73 g, 2.8 mmol) in
acetone (20
mL) was refluxed for 16 h. The mixture was cooled, concentrated, taken up in
H20,
extracted with ether and purified by flash column chromatography (25 %
EtOAc/Hexane)
to afford the title compound (0.232 g) as a clear oil. 1H-NMR (250 MHz,
CDCl3): S 2.70-
2.73 (m, 1H), 2.85-2.89 (m, 1H), 3.30-3.32 (m, 1H), 3.53 (s , 2H), 3.59 (s,
3H), 3.87-3.94
(m, 1H), 3.98 (s, 2H), 4.18 (dd, J=5.4, 11.4 Hz, 1H), 6.70-7.29 (m, SH).
d) (R)-1-[1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(3-benzyl-4
methoxycarbonylmethyl)phenoxy]-propan-2-of hydrochloride salt
A mixture of the compound of Example 3(c) (0.37 mmol), and 4-methoxyphenyl-l,l-
dimethylethylamine (0.2 g, 1.11 mmol) in ethanol (20 mL) was heated at reflux
for 24 h.
The mixture was cooled, concentrated and purified by flash column
chromatography (5%
MeOH/ CHCI3) to afford as a colorless oil (0.110 g) which (0.020 g) was
stirred in
methanol and added 4M HCI, concentrated and triturated in ether to give the
title
compound (0.020 g). ESMS {M+H)+ m/e 492.3.
Example 4
Preparation of (R)-1-11 1-dimethyl-2-(2-napht~l)ethylaminol-3-I(3-benzyl-4-
methoxvcarbonylmethyl)phenoxyl- ropan-2-of hydrochloride salt
A mixture of the compound of Example 3(c) (0.37 mmol), and 2-naphthylphenyl-
1,1-dimethyl ethylamine (0.22 g, 1.12 mmol) in ethanol (20 mL) was heated at
reflux for 24
h. The mixture was cooled, concentrated and purified by flash column
chromatography
(5% MeOH/ CHC13) to afford as a colorless oil (0.100 g) which (0.020 g) was
stirred in
methanol and added 4M HCI, concentrated and triturated in ether to give the
title
compound (0.025 g). ESMS (M+H)+ m/e S I2.4.
27
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Example 5
Preparation of (R)-1-f 1.I-dimethyl-2-(2-naphthyl)ethylaminol-3-f(3-benzyl 4
carboxymethyl)phenol-propan-2-of ~drochloride salt
A mixture of the compound of Example 4 (0.15 I mmol), and 1 M NaOH (0.200
mL), was dissolved in methanol (2 mL) and stirred for 24 h. The reaction was
quenched
with 1M HCI, extracted with CHCl3, dried with MgS04, filtered and evaporated
to afford a
white powder {0.05 g). ESMS (M+H)+ m/e 498.3.
Examale 6
Preparation of (R)-1-f 1 1-dimethyl-2-(4-methoxyphenyl)ethylaminol 3 f(3
benzyl 4
carboxvmethyl)phenox ~Ll-pr~an-2-of hydrochloride salt
A mixture of the compound of Example 3 (0.173 mmol), and 1M NaOH (2.0 mL),
was dissolved in methanol (5 mL) and stirred for 48 h. The reaction was
quenched with 1M
HCI, extracted with CHC13, dried with MgS04, filtered and evaporated to afford
a white
powder (0.03 g). ESMS (M+H)+ m/e 478.3.
Example 7
Preparation of (R)-1-f 1 1-dimethyl-2-(4-methoxyphenyl)ethylaminol 3 f(4 (3
hydroxy)propy~phenoxvl-~ro~an-2-of (~rdrochloride salt
A mixture of 3-p-hydroxyphenylpropanol (Aldrich, 1 g, 6.5 mmol), K2C03 ( 1.1
g,
7.8 mmol), and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (2.1 g, 8.2 mmol) in
acetone (30
mL) was refluxed for 24 h. The mixture was cooled, concentrated, taken up in
H20 and
extracted with diethyl ether. The organic extracts were washed with 5% NaHC03;
brine,
dried over MgS04, filtered, and concentrated. This compound (0.35 g, 1.68
mmol), and 4-
methoxyphenyl-1,1-dimethyl ethylamine (0.331 g, 1.89 mmol) in ethanol (10 mL)
was
heated at reflux for 24 h. The mixture was cooled, concentrated and purified
by flash
column chromatography (5% MeOH/ CHC13) to afford an oil which was stirred in
28
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
methanol and added 4M HCI, concentrated and triturated in ether to give a
white powder of
the title compound (0.15 g). ESMS (M+H)+ m/e 388.3.
Example 8
Preparation of (R)-1-f 1.1-dimethyl-2-(4-methoxyphe~l)eth~rlaminol-3-f(4-(2-
hydroxy)ethyl)phenox ~Ll-pro_pan-2-of hydrochloride salt
A mixture of 4-hydroxyphenylethyl alcohol (Aldrich, 1 g, 7.25 mmol), K2CO3 (
1.2
g, 8.7 mmol), and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (2.07 g, 8.0 mmol)
in acetone
(30 mL) was refluxed for 24 h. The mixture was cooled, concentrated, taken up
in H20 and
extracted with diethyl ether. The organic extracts were washed with 5% NaHC03,
brine,
dried over MgS04, filtered, and concentrated. This compound (0.394 g, 2.03
mmol), and
4-methoxyphenyl-l,l-dimethyl ethylamine (0.400 g, 2.23 mmol) in ethanol (10
mL) was
heated at reflex for 24 h. The mixture was cooled, concentrated and purified
by flash
column chromatography (5% MeOH/ CHCl3) to afford an oil which was stirred in
methanol and added 4M HCI, concentrated and triturated in ether to give the
title
compound as a white powder of (0.11 g). ESMS (M+H)+ m/e 374.4.
Example 9
Preparation of (R)-1-f 1.1-dimeth~l-2 4-methoxyphen l~,ylamino]-3-f(4-d2-
cyano)ethyl~pheno~l-propan-2-of hydrochloride salt
A mixture of 4-hydroxyphenyl propionitrile (Lancasater, 1 g, 6.8 mmol), K2C03
(2.8 g, 20.4 mmol), and 2R-(-)-glycidyl-3-nitrobenzenesulfonate ( 1.76 g, 6.8
mmol) in
acetone (30 mL) was refluxed for 24 h. The mixture was cooled, concentrated,
taken up in
H20 and extracted with diethyl ether. The organic extracts were washed with 5%
NaHC03,
brine, dried over MgS04, filtered, and concentrated. This compound (0.28 g,
1.38 mmol),
and 4-methoxyphenyl-1,1-dimethyl ethylamine (0.272 g, 1.52 mmol) in ethanol (5
mL) was
heated at reflex for 24 h. The mixture was cooled, concentrated and purified
by flash
column chromatography (5% MeOH/ CHCl3) to afford an oil which was stirred in
29
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
methanol and added 4M HCI, concentrated and triturated in ether to give the
title
compound as a white powder (0.25 g). ESMS (M+H)+ m/e 483.3.
Example 10
Preparation of lR)-Methvl 2-f4-f3-f2-l4-methoxyphenyl)-I 1-dimethylethylaminol
~
h_ydroxvpropoxylbenzovlbenzoate hydrochloride salt
a) (R)-Methyl 4-(oxiranylmethoxy)phenylbenzoyl) benzoic ester
The material purchased from ICN, 2-(4-hydroxybenzoyl) benzoic acid, (3.5 g,
14.5 mmol)
was dissolved in methanol (50 mL) and was treated with concentrated H2S04 (0.5
mL) at
reflux for 16 h. The mixture was cooled, evaporated, taken up in 5% NaHC03 and
extracted into diethyl ether. A mixture of this crude compound (3.07 g, 11.99
mmol),
K2C03 (4.97 g, 36 mmol), and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (3.2 g,
11.99
mmol) in acetone (50 mL) was refluxed for 24 h. The mixture was cooled,
concentrated,
taken up in H20, extracted with EtOAc. The organic extracts were washed with
saturated
NaHC03, brine, dried over MgS04, filtered, concentrated and purified by flash
column
chromatography (50 % EtOAc/Hexane) to afford the title compound (3.48 g) as an
off
white foam. 1H-NMR (250 MHz, CDCl3): 8 2.70-2.73 (m, 1H), 2.91-2.99 (m, 1H),
3.32-
3.45 (m, 1H), 3.61 (s , 3H), 3.91-3.99 (m, 1H), 4.35 (dd, J=5.3, 11.4 Hz, IH),
6.80-8.0 (m,
8H).
b) (R)-Methyl 2-[4-[3-[2-(4-methoxyphenyl}-1,1-dimethylethylamino]-2-
hydroxypropoxy]benzoylbenzoate hydrochloride salt
A mixture of the compound from Example 10 (a) ( 1.75 g, 6.25 mmol), and 4-
methoxyphenyl-1,1-dimethyl ethylamine (1.11 g, 6.25 mmol) in ethanol (5 mL)
was heated
at reflux for 16 h. The mixture was cooled, concentrated and purified by flash
column
chromatography (5% MeOH/ CHC13) to afford an oil ( 1.27 g) of which (0.384 g)
was
stirred in methanol and added 4M HCI, concentrated and triturated in ether to
give the title
compound as a white powder (0.28 g). ESMS (M+H)+ m/e 492Ø
Example I1
CA 02327279 2000-10-03
WO 99/515b9 PCT/US99/07722
Preparation of (R)-2-f4-f3-f2-(4-Methoxyphen-yl)-1.1-dimethylethylaminol-2-
hydroxypropoxvlbenzoylbenzoic acid hydrochloride salt
A mixture of the compound of Example 10 (b)(0.30 g, 0.61 mmol), and 1M NaOH
( 1 mL), was dissolved in methanol (5 mL) and stirred at rt for 12 h then
reflux for 5 h. The
reaction was quenched with 1M HCI, extracted with CHCl3, dried with MgS04,
filtered
and evaporated to afford a white powder (0.125 g). ESMS (M+H)+ m/e 487.1:
Example 12
Preparation of (R)-1-f 1.1-dimethyI-2-(4-methoxyphenyl)etl~laminol-3-f(4-
cyanomethyl)phenoxyl-propan-2-of hydrochloride salt
A mixture of 4-hydroxybenzylcyanide (Aldrich, 1 g, 7.51 mmol), K2C03 (3.1 g,
22 mmol), and 2R-(-)-glycidyl-3-nitrobenzenesulfonate ( 1.95 g, 7.51 mmol) in
acetone (25
mL) was refluxed for 16 h. The mixture was cooled, concentrated, taken up in
H20 and
extracted with diethyl ether. The organic extracts were washed with 5% NaHC03,
brine,
dried over MgS04, filtered, and concentrated. This compound (0.250 g, 1.3
mmol), and 4-
methoxyphenyl-1,1-dimethyl ethylamine (0.255 g, 1.43 mmol) in ethanol (10 mL)
was
heated at reflux for 16 h. The mixture was cooled, concentrated and purified
by flash
column chromatography (5% MeOH/ CHCl3) to afford an oil which was stirred in
methanol and added 4M HCI, concentrated and triturated in ether to give the
title
compound as a white powder (0.100 g). ESMS (M+H)+ m/e 369.1.
Example 13
Preparation of lR)-1-f 1.1-dimethyl-2-j4-methoxyphenyl)ethylaminol-3-f (4-
cyano)phenoxyl-propan-2-of hydrochloride salt
A mixture of 4-cyanophenol (Aldrich, 1 g, 8.40 mmol), K2C03 (3.5 g, 25 mmol),
and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (2.18 g, 8.4 mmol) in acetone (25
mL) was
refluxed for 16 h. The mixture was cooled, concentrated, taken up in H20 and
extracted
with diethyl ether. The organic extracts were washed with saturated NaHC03,
brine, dried
31
CA 02327279 2000-10-03
WO 99/51569 PC'T/US99/07722
over MgS04, filtered, and concentrated. This compound (0.260 g, 1.5 mmol) and
4- '
methoxyphenyl-1,1-dimethyl ethylamine (0.269 g, 1.5 mmol) in ethanol (10 mL)
was
heated at reflux for 16 h. The mixture was cooled, concentrated and purified
by flash
column chromatography (5% MeOH/ CHC13) to afford an oil which was stirred in
methanol and added 4M HCI, concentrated and triturated in ether to give the
title
compound as a white powder (0.060 g). ESMS (M+H)+ mle 355.1.
Example 14
Preparation of (R)-1-f 1 I-dimethyl-2-(4-methoxyphenyl)ethylaminol 3 f(4
methoxvcarbonvlmethyl)phenoxyl-nropan-2-of hydrochloride salt
A mixture of methyl-4-hydroxyphenylacetate (Aldrich, 0.500 g, 2.99 mmol),
K2C03 ( I.24 g, 8.89 mmol), and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (0.777
g, 2.99
mmol) in acetone ( 10 mL) was refluxed for 16 h. The mixture was cooled,
concentrated,
taken up in H20 and extracted with diethyl ether. The organic extracts were
washed with
5% NaHC03, brine, dried over MgS04, filtered, and concentrated. This compound
(0.200
g, 1.12 mmol) and 4-methoxyphenyi-1,1-dimethyl ethylamine (0.250 g, 1.12 mmol)
in
ethanol ( 10 mL) was heated at reflux for 16 h. The mixture was cooled,
concentrated and
purified by flash column chromatography (5% MeOH/ CHCl3) to afford an oil
(0.266 g) of
which 80 mg was stirred in methanol and added 4M HCI, concentrated and
triturated in
ether to give the title compound (0.060 g) with minor impurity of ethyl ester.
ESMS
(M+H)+ m/e 402.2 & 416.4.
Example 15
Preparation of (R)-1-fl 1-dimethyl-2-(4-methoxyphenylethylaminol 3 f(2 vitro 4
cyano)ohen~propan-2-of hydrochloride salt
A mixture of 4-hydroxy-3-nitrobenzonitrile (Aldrich, 0.500 g, 3.05 mmol),
K2C03
(1.26 g, 9.15 mmol), and 2R-(-)-glycidy(-3-nitrobenzenesulfonate (0.790 g,
3.05 mmol) in
acetone ( 10 mL) was refluxed for 16 h. The mixture was cooled, concentrated,
taken up in
H20 and extracted with diethyl ether. The organic extracts were washed with 5%
NaHC03,
32
CA 02327279 2000-10-03
WO 99/51569 PCTNS99/07722
brine, dried over MgS04, filtered, and concentrated. This compound (0.100 g,
0.45 mmol)
and 4-methoxyphenyl-1,1-dimethyl ethylamine (0.085 g, 0.45 mmol) in ethanol
(10 mL,)
was heated at reflux for 16 h. The mixture was cooled, concentrated and
purified by flash
column chromatography (5% MeOH/ CHC13) to afford an oil which was stirred in
methanol and added 4M HCI, concentrated and triterated in ether to give the
title
compound (0.030 g). ESMS (M+H)+ m/e 400.1.
Example 16
Preparation of (R)-I-f 1 1-Dimethyl-2-(4-methox~rphenyl)ethylaminol 3 l(~
nitro 4
(hvdroxvmethyl))phenoxy~-propan-2-of ~drochloride salt
A mixture of 4-hydroxy-3-nitrobenzyl alcohol (Aldrich, 0.500 g, 2.96 mmol),
K2C03 ( 1.22 g, 8.87 mmol) and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (0.767
g, 2.96
mmol) in acetone ( 10 mL) was refluxed for 16 h. The mixture was cooled,
concentrated,
taken up in H20 and extracted with diethyl ether. The organic extracts were
washed with
S% NaHC03, brine, dried over MgS04, filtered, and concentrated. This compound
(0.252
g, 1.12 mmol) and 4-methoxyphenyl-I,1-dimethyl ethylamine (0.200 g, 1.12 mmol)
in
ethanol ( 10 mL) was heated at reflux for 16 h. The mixture was cooled,
concentrated and
purified by flash column chromatography (5% MeOH/ CHC13) to afford an oil
which was
stirred in methanol and added 4M HCI, concentrated and triturated in ether to
give the title
compound (0.250 g). ESMS (M+H)+ m/e 405.1.
Example 17
Preparation of (R)-I-f 1 1-Dimethyl-2-(4-methox~nhenyl)ethylaminol 3 f(2 nitro
4
methoxvcarbonvlmeth~phenox ~Ll-propan-2-of hydrochloride salt
a) (R)-Methyl 4-(oxiranylmethoxy)-3-nitrophenylacetate
The material purchased from Aldrich, 4-hydroxy-3-nitrophenyl acetic acid,
(0.500 g, 2.54
mmol} was dissolved in methanol (5 mL) and was treated with concentrated H2S04
(0.25
mL) at reflux for 16 h. The mixture was cooled, evaporated, taken up in 5%
NaHC03 and
extracted into ethyl ether. A mixture of this crude compound (0.512 g, 2.43
mmol),
33
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
K2C03 ( 1.0 g, 7.27 mmol) and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (0.630.
g, 2.43
mmol) in acetone (10 mL) was refluxed for 24 h. The mixture was cooled,
concentrated
and purified by flash column chromatography (50 % EtOAc/Hexane) to afford the
title
compound (0.59 g) as an off white foam. 1H-NMR (250 MHz, CDCl3): 8 2.84-2.93
(m,
2H), 3.37-3.450 (m, 1 H), 3.62 (s, 2H), 3.71 (s , 3H), 4.09-4.16 (m, 1 H),
4.37-4.42 (m, 1 H),
7.1-7.8 (m, 3H).
b) (R)-1-[1,1-Dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-nitro-4-
methoxycarbonylmethyl)phenoxy]-propan-2-of hydrochloride salt
A mixture of the compound from Example 17 (a) (0.298 g, 1.12 mmol), and 4-
methoxyphenyl-1,1-dimethyl ethylamine (0.200 g, 1.12 mmol) in ethanol (10 mL)
was
heated at reflux for 16 h. The mixture was cooled, concentrated and purified
by flash
column chromatography (5% MeOH/ CHC13) to afford an oil (0.345 g) of which
(0.110 g)
was stirred in methanol and added 4M HCI, concentrated and triturated in ether
to give a
white powder of the title compound (0.067 g) with minor impurity of ethyl
ester. ESMS
(M+H)+ m/e 447.2 & 461.2.
Example 18
Preparation of (R)-1-11 1-Dimethyl-2-(4-methoxynhenyl)ethylaminol 3 1(2 nitro
4
carboxvmethvl)phenoxyl-propan-2-of hydrochloride salt
A mixture of the compound of Example 17(b)( 0.23 g, 0.51 mmol), and 1M NaOH
( 1.2 mL), was dissolved in methanol (5 mL) and stirred at rt for 24 h. The
reaction was
quenched with IM HCI, extracted with CHC13, dried with MgS04, filtered and
evaporated
to afford the title compound as a white powder (0.060 g). ESMS (M+H)+ m/e
433.2.
Example 19
Preparation of (R)-1-f 1 1-Dimethyl-2-(2-naphth l~hylaminol 3 1(4
methoxycarbonylphenoxyl-propan-2-of hydrochloride salt
(a) Methyl 4-(R)-glycidylbenzoate
34
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Methyl 4-hydroxybenzoate ( 1.0 g, 6.57 mmol, Aldrich) in acetone was treated
with K2C03
(2.72 g, 19.71 mmol) and 2R-(-)-glycidyl-3-nitrobenzenesulfonate (1.7 g, 6.57
mmol) and
the solution heated at reflux for 24 h. The reaction mixture was filtered and
the filtrate
evalorated at reduced pressure. The residue was washed with S°lo Na2C03
(aqueous), dried
over anhydrous MgS04 and evaporated to give methyl 4-(R)-glycidylbenzoate
which was
used without further purifcation in the next step.
(b) (R)-1-[ l,1-Dimethyl-2-(2-naphthyl)ethylamino]-3-[(4-
methoxycarbonyl)phenoxy]-
propan-2-of hydrochloride salt
The epoxide from Example 19(a) (380 mg, 1.82 mmol) was treated with 1,1-
dimethyl-2-(2-
napthy()ethylamine (364 mg, 1.82 mmol) in ethanol was heated at reflux for 24
h. The
reaction mixture was evaporated and the residue purified by flash
chromatography (silica
gel, 3°!o MeOH in CHCl3) to give the above titled product (344 mg). ES
MS (M+H)+ m/e
408.
Example 20
Preparation of (R)-1-f 1 1-Dimethyl-2-(2-naphthyl)ethylaminol-3 fl4
carboxy)phenoxyl
propan-2-of hydrochloride salt
The ester from Example 19(b) (281 mg, 0.69 mmol) in dioxane (4 mL) was treated
with 1.4 mI. of 1N NaOH (aqueous) at room temperature for 190 h. The reaction
mixture
was acidified with 3 N HCl (aqueous) and evaporated. The residue was washed
with water
and then azeotroped from CH2Cl2 to give the above titled compound (194 mg). ES
MS
(M+H)+ m/e 394.
Example 21
Preparation of (R)-1-f 1 1-dimethyl-2-(4-metho~phenyl)ethylaminol 3 f(2 c ano-
4
ethoxvcarbonylmethyl,)phenoxyl-propan-2-of
(a) Ethyl (2-cyano-4-oxyacetyl)phenylacetate
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
A solution of ethyl-4-hydroxyphenylacetate (2.34g, 13 mmol), SnCl4 (0.15 mL,
1.3 mmol)
and tributylamine ( 1.2 mL, 5.2 mmol) in toluene (100 mL) was stirred at RT
for 20 min
under an argon atmosphere. Paraformaldehyde (0.86 g) was added and the
solution was
heated at reflux for 18 h. The solution was cooled to RT and poured into water
and
acidified with aqueous HCl (3M) to pH 2 (litmus paper). Ethylacetate was added
and the
layers separated. The organic layer was washed with water and brine and
concentrated to
an oil which was used without purification in the next step.
The above oil, hydroxylamine hydrochloride (0.69g, 10 mmol) and
diisopropylethylamine ( 1.3g, IOmmole).in EtOH (20 mL) were heated at reflux
under an
argon atmosphere. After 18 h the solution was concentrated to give 2.1g of an
oil which
was used in the next step without further purification.
A solution of the above oil in acetic anhydride (30 mL) was heated at reflux
for 30
min. The solution was then concentrated. Flash chromatography (silica gel, 30%
EtOAc/Hexane) yielded 0.7g (22%) of the title compound. IH-NMR (400 MHz,
CDCl3) 8
1.2-1.3 (m, 3H), 2.4 (s, 3H), 3.6 (s, 2H), 4.1-4.2 (q, 2H), 7.1-7.8 (m, 3H).
(b) (2R)-Glycidyl-[ethyl-2-cyano-4-hydroxyphenylJacetate
A solution of ethyl-(2-cyano-4-hydroxyphenyl)acetate (O.Sg, 2 mmol) in
EtOH/water ( 1:1,
10 mL) was treated with K2C03 (0.28g, 2 mmol). After 3 h the solution was
concentrated.
The residue was partitioned between EtOAc/water and aqueous HCl (1M) was added
to
adjust the solution to pH 2 (litmus paper). The EtOAc layer was separated and
washed with
water and concentrated to give 0.42g of an oil.
A solution of the above oil (0.42g, 2 mmol), (2R)-gycidyl 3-
nitrobenzenesulfonate
(Aldrich Chemicals, 0.52g, 2 mmol) and K2C03 (0.28g, 2 mmol) in acetone (20
mL) was
heated at reflux for 18 h. The solution was cooled and filtered. The filtrate
was
concentrated to an oil. Flash chromatography (silica gel, 20% EtOAc/Hexane)
yielded 0.4g
(77%)of the title compound. 1H-NMR (400 MHz, CDC13) 8 1.2-1.3 (m, 3H), 2.7 (m,
1H),
2.8 (m. IH), 3.4 (m, IH), 3.6 (s, 2H), 4.0-4.2 (m, 3H), 4.4 (m, IH), 7.0-7.5
(m, 3H).
36
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07~22
(c) (R)-1-[1,1-dimethyl-2-(4-methoxyphenyl)ethylamino]-3-[(2-cyano-4-
ethoxycarbonylmethyl)phenoxy]-propan-2-of
A mixture of (2R)-glycidyl-(ethyl-2-cyano-4-hydroxyphenyl)acetate
0.2g, 0.77 mmol), and 4-methoxyphenyl-1,1-dimethylethylamine (0.138 g, 0.77
mmol) in
ethanol (20 mL) was heated at reflux for 24 h. The mixture was cooled,
concentrated and
purified by flash column chromatography on silica gel (5% MeOH/ CH2Cl2) to
afford the
title compound as a colorless oil (0.207g, 61 %). ES MS (M+H)+ m/e 441.2.
Example 22
Preparation of (R)-1-f 1 1-dimethyl-2-(4-methoxyphe~l)ethylaminol 3 fl2 cyano
4
carboxvmethyl)phenoxyl-propan-2-of
The compound of Example 21 (O.100g, 0. 23mmo1) was dissolved in methanol (10
mL) and
was stirred with lM NaOH aq (3 mL) at RT for 18 h. The reaction was
concentrated in
vacuo. The residue was treated with 2 ml of water and the pH adjusted to 5
with 1M HCI.
The resulting gum was removed and concentrated twice from EtOH. Trituration
with ether
afforded a white powder (0.08g, 84%). ES MS (M+H)+ m/e 413.2
Example 23
Preparation of (R)-I-f 1 1-dimethyl-2-(4-methoxyphenyl)ethylaminol 3 ,[(4
methoxvcarbonylethyl)phenoxyl-propan-2-of
(a) (R)-Glycidyl-methyl-3-(4-hydroxyphenyl)propionate.
A solution of methyl-3-(4-hydroxyphenyl)propionate(Aldrich Chemicals,1.8g, 10
mmole),
(R)-gycidol (Aldrich Chemica1s0.74g, 10 mmol), triphenylphosphine (2.62g, 10
mmole)
and diisopropyl azodicarboxylate (2.02g, 10 mmole) in 50 ml THF was stirred at
RT for 18
h.The solution was filtered and the filtrate concentrated in vacuo. Flash
chromatography
(silica gel, CH2C12) afforded 1.33g (56%)of the title compound. IH-NMR (400
MHz,
37
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
CDCl3) 8 2.6 (m, 2H), 2.7 (m, 1H), 2.9 (m. 3H), 3.4 (m, 1H), 3.6 (s, 3H), 3.9
(m, 1H), 4.2
(m, 1H), 6.8-7.2 (m, 4H).
(b) (R)-1-[l,l-dimethyl-2-(4-methoxyphenyt)ethylamino]-3-[(4-
methoxycarbonylethyl)phenoxy]-propan-2-of
A mixture of (2R)-glycidyl-(ethyl-4-hydroxyphenyl)acetate(0.2g, 0.85mmol), and
4-
methoxyphenyl-l,l-dimethylethylamine (0.15 g, 0.85mmo1) in ethanol (20 mL) was
heated
at reflux for 24 h. The mixture was cooled, concentrated and purified by flash
column
chromatography on silica gel (5% MeOH/CH2Cl2) to afford the title compound as
a
colorless oil (0.178g, 51 %). ESMS (M+H)+ m/e 416.3.
afforded a white powder (0.081 g, 70%). ESMS (M+H)+ m/e 402.3
Example 24
Preparation of N-f2R-hydroxy-3-ff2-nitro-4-f2S-ethoxycarbonxl 2
fmethvlsulfonvllaminolphenoxvlpropyll-1 I-dimethyl 2 f4
methoxyphenylleth~rlamine
hydrochloride
(a) Methyl- 2S-amino-3-[[3-nitro-4-hydroxy)phenyl]propionate
A solution of 3-nitro-L-tyrosine (25g, 110.54 mmole) in methanol (250 mL, pre-
saturated
with HCl gas) was heated at reflux for 16h. The mixture was cooled,
concentrated, taken
up in H20, neutralized with K2C03(s), filtered the orange solid, washed with
H20, dried
by air (22g, 83%). 1H-NMR (400 MHz, DMSO-d6) 8 2.75 (dd, J=7.6, 13.6 Hz, 1H),
2.84
(dd, J=.76, 13.6 Hz, 1H), 3.55 (m, 1H), 3.60 (s, 3H), 7.04 (d, J=8.5 Hz, 1H),
7.35 (d, J = 8.5
Hz, 1H), 7.71 (s, 1H).
(b) Methyl- 2S-[methylsulfonyl)amino-3-[[3-nitro-4-hydroxy]phenyl]propionate
To a stirred mixture of Example 24(a) ( I g, 4.16 mmole), and pyridine (0.338,
4.16 mmole)
in dried THF (30 mL) was added methanesulfonylchloride (0.48g, 4.16 mmole).
After
stirring at RT overnight, the mixture was concentrated, taken up in H20,
extracted with
EtOAc, washed with 5% HCI, saturated NaHC03, brine, dried over MgS04,
concentrated
to give a light brown oil (0.98g, 74%). 1H-NMR (400 MHz, DMSO-d6): 8 2.70 (s,
3H},
2.85 (dd, J=i 1.2, 14.1 Hz, 1H), 3.05 (dd, 4.9, 11.2 Hz, 1H}, 3.67 (s, 3H),
4.20 (m, IH), 7.07
38
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(d, J = 8.5 Hz, 1 H}, 7.47 (dd, J = 1.8, 8.5 Hz, I H), 7.82 (d, J = ( . 8 Hz,
1 H), 7.9 (d, J = 8.
Hz, 1 H).
(c) Methyl- 2S-[methylsulfonyl]amino-3-[[3-vitro-4-R-
glycidyljphenyl]propionate
A mixture of Example 24(b) (0.98g, 3.08 mmole), K2C03 (0.85g, 6.16 mmole), and
2R-
glycidyl-3-nitrobenzenesulfonate (0.83g, 3.23 mmole) in acetone (20 mL) was
heated at
reflux in 24h. The mixture was concentrated, taken up in H20, extratcted with
EtOAc. The
organic extracts were washed with brine, dried over MgS04, concentrated,
purified by flash
column chromatography (50% EtOAc/Hexane) to afford a light yellow oil (0.4g,
35%).
1 H-NMR (400 MHz, CDCI3) 8 2.70 (s, 3H), 2.82 (dd, J = 4.9, 11.2 Hz, 1 H),
2.88 (dd, J =
4.9, 11.2 Hz, IH), 3.32 (m, IH), 3.51 (dd, J=I 1.2, 14.1 Hz, 1H), 3.55 (dd,
4.9, 11.2 Hz, 1H),
3.7 (s, 3H), 4.10 (dd, J = 4.9, 11.2 Hz, 1H), 4.33 (dd, J = 2.2, 4.9 Hz,
1H),5.10 (dd, J + 4.9,
11.2 Hz, 1H), 6.97 (dd, J = 1.8, 8.5 Hz, 1H), 7.36 (dd, J = 1.8, 8.5, 1H),
7.64 (s, IH).
(d) N-[2R-hydroxy-3-[[2-vitro-4-[2S-ethoxycarbonyl-2-
[methylsulfonyl]aminojphenoxyjpropylj-1, I-dimethyl-2-[4-
methoxyphenyljethylamine
hydrochloride
A mixture of Example 24(c) (0.22g, 0.59 mmole), LiC104, and 1,1-dimethyl-2-[4-
methoxyphenyl]ethylamine (0.13g, 0.7102 mmole) in EtOH (SmL) was heated at
reflux in
24h. The mixture was cooled, concentrated, taken up in H20, extracted with
EtOAc. The
organic extracts were dried over MgS04, concentrated, and purified by flash
column
chromatography (3% MeOH/CH2C12) to afford a yellow oil, which was dissolved in
THF
and added 4M Hcl in p-dioxane, concentrated, and co-evaporated with ether to
give an off
white foam (0.26 g, 79%). IH-NMR (400 MHz, CDC13) 8 1.17 (s, 6H), 2.63 (s,IH),
2.77
(s, 2H), 2.87 (dd, J = 4.9, 11.2 Hz, 1H), 3.07 (m, 3H), 3.17 (dd, J = 4.9,
11.2 Hz, 1H), 3.69
(m, IH), 3.70 (s, 3H), 4.14 (s, 3H), 4.37 (t, J -7.2 Hz, 1H), 6.81 (dd, J =
1.8, 8.5 Hz, 1H),
7.10 (m, 3H), 7.45 (dd, J = 1.8, 8.5 Hz, 1H), 7.72 (s, 1H).
Example 25
Preparation of N-f 2R-hydroxy-3-f f 2-vitro-4-f 2S methoxycarbonyl 2
fohthalimidolohenoxvlnro~yll-1 I-dimethvl-2-fnaphthyllethylamine hydrochloride
39
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(a) Methyl- 2S-[phthalimido]-3-[[3-nitro-4-hydroxy]phenyl]propionate
A mixture of Example 24(a) (Sg, 20.82 mmole), and phthalic anhydride (3.4g,
22.9 mmole)
in CHCI3 ( 150 mL) was heated at reflux in 24h. To the mixture was added Et3N
( 10.6g,
104.08 mmole), and cooled, concentrated, taken up in H20, extracted with
EtOAc. The
organic extracts were washed with 6N HCI, saturated Na2HC03, brine, dried over
MgS04,
concentrated to afford a yellow oil (7g, 91 %). 1 H-NMR (400 MHz, DMSO-d6) b
3.24 (dd,
J = 11.2, 14.1 Hz, 1 H), 3.45 (dd, J = 4.9, 11.2 Hz, 1 H), 3.70 (s, 3H), 5.28
(dd, J= 4.9, 11.2
Hz, 1 H), 6.95 (d, 8.3 Hz, 1 H), 7.34 (dd, J = 2.3, 8.3 Hz, 1 H), 7.70 (d, J =
2.3 Hz, 1 H), 7.87
(m, 4H).
(b) Methyl- 2S-[phthalimido]-3-[[3-nitro-4-R-glycidyl]phenyl]propionate
Following the example 24(c), the title compound was prepared as a tan solid
(7.9g, 98%).
1H-NMR (400 MHz, CDCI3) F~ 2.82 (dd, J = 4.9, 111.2 Hz, 1H), 2.88 (dd, J =
4.9, 11.2 Hz,
1H), 3.32 (m, 1H), 3.51 (dd, J = 11.2, 14.1 Hz, 1H}, 3.55 (dd, J = 4.9, 11.2
Hz, 1H), 3.7 (s,
3H), 4.10 (dd, J = 4.9, 11.2 Hz, 1H), 4.33 (dd, J = 2.2, 4.9 Hz, 1H), 5.10
(dd, J = 4.9, 11.2
Hz, 1 H), 6.97 (dd, J = 1.8, 8.5 Hz, 1 H), 7.36 {dd, J =1.8, 8.5 Hz, 1 H),
7.64 (s, 1 H), 7.73 (m,
2H), 7.81 (m, 2H).
(c) N-[2R-hydroxy-3-[[2-nitro-4-[2S-methoxycarbonyl-2-
[phthalimido]phenoxy]propyl]-
1,1-dimethyl-2-[naphthyl]ethylamine hydrochloride
A mixture of Example 25(b) (lg, 2.35 mmole), LiC104 0.65g, 4.69 mmole), and
1,1-
dimethyl-2-napthylamine (0.47g, 2.35 mmole) in MeCN (20 mL) was heated at
reflux in
24h. The mixture was cooled, concentrated, taken up in H20, extracted with
EtOAc. The
organic extracts were washed with brine, dried over MgS04, concentrated and
purified by
flash column chromatography (3% MeOH/CH2C12) to afford a light yellow foam,
which
was dissolved in ether and added 4M HCI in p-dioxane, concentrated, and co-
evaporated
with ether/hexane to give an off white solid (1.08g, 74%). 1H-NMR (400 MHz,
CDC13)
8 1.35 (s, 6H), 3.10 (s, 2H), 3.3 (m, 2H), 3.53 (m, 2H), 3.78 (s, 3H), 3.98
(m, IH), 4.14 (m,
1 H), 4.37 (m, 1 H), 5.06 (m, 1 H), 6.91 (d, J = 8.5 Hz, 1 H), 7.30 (m, 2H),
7.41 (m, 2H), 7.79
(m, 9H).
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Example 26
Preparation of N-f 2R-hvdroxv-3-f f 2-vitro-4-f 2S-carbox ~-~2-f f f 2-
carboxyjphenYll
carbonvllaminolethyllphenoxylpropyll-1 I-dimethyl-2-fnaphthyllet~lamine
(a} N-[2R-hydroxy-3-[[2-vitro-4-[2S-carboxy-2-[[[2-carboxy]phenyl]
carbonyl]amino)ethyl]phenoxyjpropyl]-1,1-dimethyl-2-[naphthyl]ethylamine
A mixture of Example 25(c} (0.20g, 0.32 mmole), and LiOH.H20 (0.03g, 0.64
mmole) in
THF/H20 (S mL, 4:1 ) was stirred at RT in 24h.The mixture was concentrated,
taken up in
H20, acidified with AcOH, filtered the solid, triturated in ether to give an
off white solid
(O.15g, 71 %). 1 H-NMR (400 MHz, DMSO-d6) 8 1.25 (s, 6H), 3.05 (m, 2H), 3.15
(s, 2H),
3.25 (m, 2H), 4.21 (m, 3H), 4.61 (m, 1H), 7.45 (m, 7H), 7.82 (m, 7H), 8.83 (d,
J = 4.9 Hz,
1H).
Example 27
Preparation of N-f 2R-hvdroxy-3-f f 2-vitro-4-f 2S-metho~carbonvl 2 f f f 2
carboxvlphenvllcarbonyllaminol ethyllphenoxylpropyll-1 1-dimethyl 2
fnaphthyllethylamine hydrochloride
(a) N-[2R-hydroxy-3-[[2-vitro-4-[2S-methoxycarbonyl-2-[[[2-
carboxy]phenyl]carbonyl]amino] ethyl]phenoxy]propyl]-1,1-dimethyl-2-
[naphthyl]ethylamine hydrochloride
A mixture of Example 25(c) (0.20g, 0.32 mmole), and LiOH.H20 (0.02g, 0.32
mmole) in
THF/H20 (5 mL, 4:1) was stirred at RT in 24h.The mixture was concentrated,
taken up in
H20, acidified with AcOH, filtered the solid, triturated in ether to give an
off white solid
(0. lOg, 50%). 1 H NMR (400 MHz, DMSO-d6) 8 1.25 (s, 6H), 3.05 (m, 2H), 3.15
(s, 2H),
3.25 (m, 2H), 3.78 (s, 3H), 4.21 (m, 3H), 4.61 (m, 1H), 7.45 (m, 7H), 7.82 (m,
7H), 8.83 (d,
J = 4.9 Hz, 1 H). 1 H-NMR (400 MHz, DMSO-d6): 8 1.25 (s, 6H), 3.05 (m, 2H),
3.15 (s,
2H), 3.25 (rn, 2H), 4.21 (m, 3H), 4.61 (m, 1H), 7.45 (m, 7H), 7.82 (m, 7H),
8.83 (d, J = 4.9
Hz, 1 H).
41
CA 02327279 2000-10-03
WO 99151569 PCT/US99/07722
Example 28
Preuaration of (R)-1-lI I-Dimethyl-2-(2-naphthyl)ethylaminol 3 1(3 (2
amino~henoxy) 4
methoxvcarbony!)phenoxyl-oropan-2-of di~drochloride salt
(a) 1-(2-Nitrophenoxy}-2-methoxycarbonyl-5-methoxy-benzene
A solution of 2-methoxycarbonyl-5-methoxyphenol (34.1g, 0.187 mol), 2-
nitrofluorobenzene (19.7 mL, 0.187 mol), and K2C03 (65 g, 0.467 mol) in DMF
(200 mL)
was heated at 1 lOoC for 18 h. The solution was diluted with water (200 mL)
and extracted
with EtOAc. The EtOAc layer was concentrated to give the crude title compound
(57
g)which was used as is for the next step without further purification.
(b) 2-Carboxymethyl-5-methoxy-phenyl-oxy-(3-aminobenzene)
A solution of compound from Example 28(a) (57 g, 0. I 87 mol) and 10% Pd/C ( 1
I g) in
MeOH ( 1000 mL) was treated with H2 at 50 psi for 2 h. The solution was
filtered through
Celite and the filtrate was concentrated. Flash chromatography (silica gel,
20%
EtOAc/Hexane) yielded the title compound (49.3 g, 96%): MS (ES) (M + H)+ m/e
274.1.
(c) 1-(2-Aminophenoxy)-2-methoxycarbonyl-5-hydroxy-benzene
To a cold solution of compound from Example 28 (b) ( 1 g, 4.1 mmol) and
ethylmercaptan
( 1.5 mL, 20 mmol) in CH2Cl2 ( 1 S mL) was added A1C13 (2.8g, 20 mmol). After
2 h at 0
°C solution was concentrated and residue was treated with ice/water (50
mL) and CH2C12
(50 mL). Organic layer was separated and washed with water (2X). The organic
layer was
concentrated to give the crude title compound (0.95g) which was used as is for
the next
step.
(d) I-(2-Aminophenoxy)-2-methoxycarbonyl-5-(2(R)-glycidyl)-benzene
A solution of compound from Example 28 (c) (0.5Ig 2.2 mmol), 2R-gycidyl 3-
nitrobenzenesulfonate (0.582g, 2.2 mmol) and K2C03 (0.93g, 6.6 mmol) in
acetone (20
mL) was heated at reflux for 18 h. The solution was filtered and the filtrate
was
concentrated to give the title compound (0.64g) which was used as is for the
next step.
42
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(e) (R)-I-[1,1-Dimethyl-2-(2-naphthyl)ethylamino]-3-[(3-(2-aminophenoxy)-4-
methoxycarbonyl)phenoxy]-propan-2-of dihydrochloride salt
A solution of compound from Example 28 (d) (0.10 g, 0.4 mmol) and 1,1-dimethyl-
2-(2-
naphthyl)ethyl amine (0.07 g, 0.4 mmol) in EtOH (5 mL) was heated to reflux
for 18 hr.
Solution was concentrated. Flash chromatography (silica gel, 5% CH30H/CH2Cl2)
and
treatment with HCl in MeOH yielded the title compound (0.1 g, 60%): I H-NMR
(400 MHz,
DMSO-d6) b 1.0-1.3 (m,BH), 3.0-4.3 (m, 11H), 6.7-8.0 (m, l IH), 8.8-8.9 (m,
IH), 9.3-9.4
(m, IH); MS (ES) (M + H)+ m/e 515Ø
Example 29
Preparation of (R)-I-fl,l-Dimeth)rl-2-(2-naphthyl)ethylaminol-3-f(3-(2-
amino~henoxy) 4
carboxy)phenoxyl-propan-2-of dihydrochloride salt
IS A solution of compound from Example 28 (e) (0.7g, 1.4 mmol) in MeOH (5 mL)
was treated with 1 N NaOH (3.0 mL, 3.0 mmol). After 18 h, the solution was
concentrated.
Water (10 mL) was added and the solution was treated with 1 N HCl to pH 7,
filtered and
the solid was dried in vacuo to give the title compound (0.35 g, 50%). MS (ES)
(M + H)+
m/e 501.1; IH-NMR (400 MHz, DMSO-d6) 8 1.2-1.3 (s, 6H), 3.1-4.3 (m, I 1H), 6.7-
7.9 (m,
13H), 8.7-8.9 (m, 1H), 9.2-9.5 (m, IH).
Formulations for pharmaceutical use incorporating compounds of the present
invention can be prepared in various forms and with numerous excipients.
Examples of
such formulations are given below.
Example 30
Preparation of (R)-N-f2-Hydroxy-3-(2-cyano-4-(2-
carboethoxyethyl,)phenoxy~propyll 1 1
dimethyl-2~2-naphthyl)ethvlamine
(a) Ethyl-3-(2-cyano-4-hydroxyphenyl)propionate
To 25.2 g (0.13 mol) of ethyl-3-(4-hydroxy-3-cyanophenyl)propionate in 300 mL
of dry
toluene was added under argon 12.4 mL (0.052 mol) of tri-n-butylamine followed
by 1.5
43
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
mL (0.013 mol) of tin(IV) chloride. After stirring for 10 min, 8.6 g of
paraformaldehyde~
was added and the reaction was refluxed under argon for 18 h.
The reaction was cooled and concentrated to a dark oil which was subjected to
flash column
chromatography on silica gel eluting with 90:10 hexane:ethyl acetate (v/v).
There was
S obtained 5.3 g of product ( 18.6%). Further elution with 70:30 hexane:ethyl
acetate (v/v)
yielded 12 g of starting material.
To a solution of 10 g (0.045 mol) of the above aldehyde in 200 mL of absolute
ethanol was
added 6.1 g (0.06 mol) of triethylamine followed by 3.48 g (0.05 mol) of
hydroxylamine
hydrochloride. The reaction was stirred under argon at reflux for 18 h. The
reaction was
concentrated. The residual oil was dissolved in ethyl acetate and washed with
1N HCI. The
ethyl acetate phase was dried, filtered and concentrated to an oil which was
treated with
100 mL of acetic anhydride and refluxed under argon for 30min. The reaction
was
concentrated. The resulting oil was dissolved in ethyl acetate and washed with
water. The
ethyl acetate layer was dried, filtered and concentrated to an oil which was
dissolved in 200
mL of ethanol and treated with a solution of 9.54 g of sodium carbonate (0.09
mol) in 50
mL of water. After stirring at room temperature for 5 h the mixture was
neutralized with 3N
HCl to pH 5 and concentrated. The resulting mixture was extracted with ethyl
acetate. The
ethyl acetate solution was dried, filtered and concentrated to an oil which
solidified on
storage: 9.5 g (97%).
(b) Ethyl-3-(2-cyano-4-(R)-glycidyloxyphenyl)propionate
A solution of 7.7 g (0.035 mol) ethyl-3-(2-cyano-4-hydroxyphenyl)propionate
and 9.1 g
(0.035 mol) of 2-(R)-glycidyl-3-nitrobenzenesulfonate in 100 mL of dry acetone
was
treated with 7.6 g (0.055 mol) of potassium carbonate and refluxed under argon
for 18 h.
The reaction was cooled and filtered. The filtrate was concentrated and
purified by flash
column chromatography on silica gel eluting with 70:30 hexane:ethyl acetate to
yield 6 g
(62%) of the epoxide.
(c) (R)-N-[2-Hydroxy-3-(2-cyano-4-(3-carboethoxyethyl)phenoxy)propyl]-1,1-
dimethyl-2-
(2-naphthyl)ethylamine
A solution of 2.69 g (0.0098 mol) of the epoxide and 1.95 g of the amine(0.098
mol) was
refluxed in 75 mL of ethanol under argon for 18 h. The reaction was
concentrated and the
44
CA 02327279 2000-10-03
WO 99/51569 PCT/US99J07722
residue was purified by flash column chromatography on silica gel eluting with
95:5
methylene chloride:methanol (v:v) to yield 4.0 g of the desired product (86%).
Example 31
Preparation of (R)-N-l2-Hvdroxv-3-(2-cyano-4-(3-carboxyethyl)phenoxy~propyll 1
l
dimethvl-2-(2-nanhthyl)et>~lamine Sodium Salt
To a stirred solution of 100 mg of the ethyl ester(0.21 mmol) in 5 mL of
ethanol was added
1 mI. of 1 N sodium hydroxide ( 1 mmol). The mixture was stirred for 4 h and
then
concentrated, diluted with 0.5 mL water and the pH adjusted to about 4 with 3N
hydrochloric acid. The mixture was decanted and the residual gum was treated
with 2 mL
of IN hydrochloric acid in methanol and concentrated. The residue was then
concentrated
four times from ethanol. The resulting solid was triturated with ether,
filtered and dried
under vacuum to give 60 mg of a white powder (64%), ES-MS, m/z 446.7 (M+H).
Example 32
Preparation of (R)-N-f2-Hvdroxv-3-(2-cyano-5- 3-
carbethoxypropy~phenoxy)propyll 1 1
dimethvl-2-(2-naphth ly )ethylamine Hydrochloride
(a) Ethyl 4-(4-cyano-3-hydroxyphenyl)butanoate
To a solution of 2-fluoro-4-bromobenzonitrile (2.0 g, 10 mmol) in 10 mL of
THF, cooled to
-15 °C, was added a solution of potassium t-butoxide ( 10 mL, 10 mmol)
over 7 min. The
cooling bath was removed, and the reaction stirred for another 40 min. The
reaction was
poured into ether/10% HCI, and the ether layer was separated. The ether layer
was washed
with water and saturated brine, dried over sodium sulfate, and concentrated to
give 2.5 g of
2-t-butoxy-4-bromobenzonitrile.
Isobutyl vinylacetate (5.69 g, 40 mmol) was placed in a dry 500 mL flask,
cooled to
0 °C, and purged with N~. A 0.5 M THF solution of 9-BBN (80 mL, 40
mmol) was added
over 5 min with ice bath cooling. The bath was removed, and the reaction was
stirred
overnight at room temperature. To 2-t-butoxy-4-bromobenzonitrile ( 10.2 g, 40
mmol) was
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
added 60 mL of dry DMF. The solution was placed under NZ, and PdClz(dppf)
(0.98 g, 1.2
mmol) was added over 1 min with vigorous stirring. The resulting solution was
added by
syringe to the above described borane solution, followed by the addition of
CsZCO~ (26.07
g, 80 mmol). The solution was heated to 90 C for 45 min then allowed to cool.
The
reaction was worked up by pouring into ether/ 5% HCI. The ether layer was
separated, and
the aqueous layer was extracted once more with ether. The combined ether
extracts were
washed with water (3 x 1 L) and brine, dried over sodium sulfate and
concentrated. The
product, isobutyl 4-(4-cyano-3-t-butoxyphenyl)butanoate, was used as is for
the next
reaction.
All of the ester from above was. dissolved in 125 mL of THF to which was added
50 mL of water containing 80 mmol of LiOH. The solution was heated to 65-72
°C for 5.5
hours, then concentrated in vacuo. The residue was taken up in ether/water and
the ether
layer separated. The aqueous layer was extracted twice more with ether to
remove any
non-acidic impurities. The aqueous layer was made acidic with HCI, and
extracted twice
with ether. The combined ether extracts were washed with brine, dried over
sodium sulfate
and concentrated to give 11.1 g of 4-(4-cyano-3-t-butoxyphenyl)butanoic acid
(still
containing some cyclooctyl impurities derived from the 9-BBN).
The above acid (approx. 40 mmol) was dissolved in dry THF and placed under NZ.
1,1'-Carbonyldiimidazole (6.81 g, 42 mmol) was added, and the reaction was
stirred for 2
hrs at room temperature. Dry ethanol (5.552 g, 120 mmol), to which NaH (80 mg,
2 mmol)
had been added, was then added to the solution and stirred at room temperature
for 1 hr
followed by heating to 50-60 °C for 3 hours. The solution was
concentrated, and the
residue taken up in ether/ 5% HCI. The ether layer was separated, washed with
water,
NaHC03 and brine, then dried over sodium sulfate and concentrated to give 9.3
g of crude
product. The crude product was chromatographed on a silica gel column (5 x 20
cm)
equilibrated in CHCI, and eluted with 4% EtOAc in CHCI,. The yield of was 7.15
g (62%
over 3 steps from 2-t-butoxy-4-bromobenzonitrile).
Ethyl 4-(4-cyano-3-t-butoxyphenyl)butanoate (6.8 g, 23.5 mmol) was dissolved
in a
mixture of acetonitrile (42 mL) and conc. HCl (3.85 mL) and allowed to stand
for 80 min.
The reaction was poured into ether/water and the ether layer separated. The
ether layer was
washed with water and brine, and the combined aqueous washes were reextracted
once with
ether. The combined ether layers were dried over sodium sulfate and
concentrated to give
5.1 g of an off white waxy solid. This material was loaded onto a silica gel
column (5 x 15
46
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
cm) in CHCIz and eluted with 20% EtOAc in CHCI, to yield 4.5 g of ethyl 4-(4-
cyano-3-
hydroxyphenyl)butanoate: 'H-NMR (CDCh} 8.2 ( 1 H, s), 7.42 ( 1 H, d), 6.95 ( 1
H, s ), 6.77
( 1 H, d), 4.2 (2H, q), 2.63 (2H, dd), 2.39 (2H, dd), 1.96 (2H, m), I .28 (3H,
t); "C-NMR
(CDCh) 174.4, 159.5, 149.2, 132.8, 120.8, I 17.0, 116.1, 97.1, 60.9, 35.2,
33.6, 25.7, 14.1.
(b) Preparation of (R)-2-cyano-5-(3-carbethoxypropyl)phenyl glycidyl ether
Using the method of example 30(b), vide supra, ethyl 4-(4-cyano-3-
hydroxyphenyl)butanoate (1.4 g, 6 mmol) and (R)-glycidyl nosylate ( 1.48 g,
5.71 mmol)
were used to prepare 1.47 g (88%) of the title compound as a white solid.
(c) (R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carbethoxypropyl)phenoxy)propyl]-1,1-
dimethyl-
2-(2-naphthyl)ethylamine Hydrochloride.
Using the method of example 30 (c), supra, (R)-2-cyano-5-(3-
carbethoxypropyl)phenyl glycidyl ether ( 1.47 g, 5.08 mmol) and 1, I-dimethyl-
2-(2-
naphthyl)ethylamine ( 1.1 g, 5.59 mmol) were used to prepare the title
compound as a white
solid: 'H-NMR (CDCl3) 9.82 (1H, br s), 8.42 (IH, br s), 7.78 (4H, m), 7.35-7.5
(4H), 6.8
(2H, m), 5.7 (IH, br s), 4.82 (1H, m), 4.25 (2H, m), 4.1 (2H, q), 3.4-3.65
(4H), 2.65 (2H,
dd), 2.3 (2H,dd), 1.95 (2H, m), 1.55 (6H, d), 1.25 (3H, t): "C-NMR (CDCIj)
173.0, 160.1,
149.4, 133.2, 133.1, 132.4, 131.9, 129.7, 128.7, 128.0, 127.7, 127.5, 126.2,
125.9, 121.7,
116.5, I 13.1, 99.8, 70.7, 65.6, 61.4, 60.4, 45.1, 44.2, 35.5, 33.4, 25.9,
23.1, 22.9, 14.2.
Example 33
Preparation of (R)-N-12-Hvdroxy-3-(2-cyano-5-(3-carbox~rpropyl~phenoxy)propyll
1 1
dimethyl-2-(2-naphthyl ethylamine Sodium Salt
(R)-N-[2-Hydroxy-3-(2-cyano-5-(3-carbethoxypropyl)phenoxy)propyl]- I, I -
dimethyl-2-(2-naphthyl)ethylamine (0.77 g, 1.58 mmol) was hydrolyzed by
stirring
overnight at room temperature in 25 mL of EtOH containing 2.37 mmol of NaOH in
2.37
mL of water. The reaction was concentrated, and the residue dissolved in 40 mL
of water.
The pH was lowered with 1 N HCl until the zwitterion form of the product
dropped out of
solution (pH approx. 6 to 6.5). The solid was faltered and washed with water.
The solid
was then suspended in 30 mL of water, and I N NaOH was added slowly until the
solid
47
CA 02327279 2000-10-03
WO 99/51569 PCT/US99I07722
went into solution (final pH approx. I 1). The solution was frozen and
lyophilized to
dryness to give 732 mg of the title compound as a white solid: 'H-NMR ( 1: I
CD~CN:D=O)
7.6-7.8 (4H), 7.4 (3H, m), 7.32 ( 1 H, d), 7.0 ( 1 H, s), 6.9 ( 1 H, d), 4. I
(2H, m), 4.0 ( 1 H, m),
3.78-3.92 (4H), 2.6 (2H, dd), 2.1 (2H, dd), 1.8 (2H, m), 1.02 (6H, d); "C-NMR
( I :1
CD,CN:DzO) 181.7, 160.8, 151.8, 136.4, 133.7, 133.5, 132.2, 129.6, 129.0,
127.7, 127.5,
126.3, 125.7, 121.9, 117.6, 113.3, 98.2, 71.4, 69.1, 53.7, 46.5, 44.5, 37.5,
36.0, 27.8, 26.1,
26Ø
Example 34
P_renaration of (R)-N-12-Hvdroxv-3-(2-cvano-S-(2-
carbethoxyethy_1)phenoxy)propyll 1 1
dimethvl-2-(2-naphthyl)ethylamine Hydrochloride
(a) Ethyl 3-(4-cyano-3-hydroxyphenyl)propionate
Trifluoromethanesulfonic anhydride (9.0 mL, I S g, 53 mmol, 1.2 equiv) was
added over a
period of 5 min to a solution of ethyl 3-(4-hydroxy-3-methoxyphenyl)propionate
(8.7 ml,,
10 g, 45 mmol, 1 equiv) and pyridine (9.0 mL, 8.8 g, 110 mmol, 2.5 equiv) in
CH~CIZ
(40 mL) cooled to 0 °C in an ice bath. The ice bath was removed and the
reaction mixture
was stirred for 24 h. The reaction mixture was concentrated. This material was
then taken
up in EtzO ( 100 mL) and washed with 0.1 M HCI (2 x 50 mL). The organic layer
was dried
(anh. NaZSO,) and concentrated (75 °C). This yielded 13.7 g (86%) of
product as a yellow
oil. The crude material (13.3 g) was flash chromatographed (1000 mi, 9:1
hex/EtOAc,
500 n~L, 4:1 hex/EtOAc) through flash silica gel (200 mm x 50 mm dia.). The
fractions
containing only product were combined and concentrated (75 °C). This
provided 12.3 g of
ethyl 3-(4-trifluromethanesulfoxy-3-methoxyphenyl)propionate as a nearly-
colorless oil.
To a mixture of ethyl 3-(4-trifluromethanesulfoxy-3-methoxyphenyl)propionate
(11.9 g, 33.4 mmol, 1 equiv) and zinc cyanide (7.8 g, 66.4 mmol, 2.0 equiv) in
deoxygenated dry DMF (60 mL) was added
tetrakis(triphenylphosphine)palladium(0)
(1.3 g, 1.1 mmol, 0.034 equiv). The reaction mixture was stirred at 120
°C for 5 h. The
reaction mixture was then filtered through Celite . The filtrate was diluted
with ~satd aq
NaHCO, ( 100 mL) and H20 ( 100 mL) and extracted with EtOAc ( 1 x 100 mL). The
organic layer was then washed with H20 (2 x 50 mL), dried (anh. NaZSO,), and
concentrated (75 °C). This gave 6.99 g (89.7%) of crude product as a
brown oil. This oil
was flash chromatographed (500 mL 9:1 hex/EtOAc, 1500 mL 3:1 hex/EtOAc)
through
48
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
flash silica gel (200 mm x 50 mm dia.). The fraction containing product was
concentrated
(75 °C) yielding 4.70 g (60.3%) of ethyl 3-(4-cyano-3-
methoxyphenyl)propionate as a
white crystalline solid.
A mixture of ethyl 3-(4-cyano-3-methoxyphenyl)propionate (3.17 g, 13.6 mmol,
1 equiv) and sodium cyanide (2.00 g, 40.8 mmol, 3.00 equiv) in DMSO (60 mL)
was stirred
at 140-180 °C for 2 h. After 2.5 hours the reaction mixture was taken
up in HBO (300 mL),
adjusted to pH 7 with AcOH (2. I mL), and extracted with EtZO ( 1 x 150 mL,).
The organic
layer was washed with HZO (2 x 50 mL), dried (anh. Na,S04), and concentrated
(75 °C).
This yielded 2.05 g (68.8%) of ethyl 4-(4-cyano-3-hydroxyphenyl)propionate as
a light
yellow crystalline solid: 'H-NMR (CDCIs) 7.42 ( 1 H, d), 7.40 ( 1 H, br s),
6.92 ( 1 H, d), 6.81
(1H, dd), 4.15 (2H, q), 2.94 (2H, dd), 2.64 (2H, dd), 1.25 (3H, t).
(b) (R)-2-cyano-5-(2-carbethoxyethyl)phenyl glycidyl ether
Using the method of example 30(b), supra, ethyl 3-(4-cyano-3-
hydroxyphenyl)propionate
(1.32 g, 6 mmol) and (R)-glycidyl nosylate (1.48 g, 5.71 mmol) were used to
prepare 1.35 g
(86%) of the title compound as a white solid.
(c) (R)-N-[2-Hydroxy-3-(2-cyano-5-(2-carbethoxyethyl)phenoxy)propyl)-1,1-
dimethyl-2-
(2-naphthyl}ethylamine Hydrochloride
Using the method of example 30(c), supra, (R)-2-cyano-5-(2-
carbethoxyethyl)phenyI
glycidyl ether ( 1.35 g, 4.9 mmol) and 1,1-dimethyl-2-(2-naphthyl)ethylamine (
1.07 g, 5.39
mmol) were used to prepare the title compound as a white solid: 'H-NMR (CDC13)
9.82
( 1 H, br m), 8.45 ( 1 H, br m), 7.7-7.8 (4H), 7.3-7.48 (4H), 6.82 (2H, m),
5.68 ( 1 H, d), 4.82
(1H, br m), 4.25 (2H, m), 4.10 (2H, q), 3.38-3.62 (4H}, 2.92 (2H, t), 2.60
(2H, t), 1.52 (6H,
d), 1.22 (3H, t); "C-NMR (CDCh) 172.12, 160.11, 148.42, 133.23, 133.18,
132.39,
131.93, 129.70, 128.73, 127.96, 127.70, 127.48, 126.16, 125.91, 121.57,
116.45, 113.07,
100.11, 70.73, 65.62, 61.46, 60.61, 45.06, 44.22, 34.96, 31.17, 23.12, 22.94,
14.14.
Example 35
P_reoaration of (R)-N-12-Hvdroxy-3-(2-cyano-5-(2-carboxyethyl,~phenoxy)propyll
1 1
dimethvl-2-(2-naphthyl)ethylamine Sodium Salt
49
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(R)-N-[2-Hydroxy-3-(2-cyano-5-(2-carbethoxyethyl)phenoxy)propyl]-1,1-dimethyl-
2-(2=
naphthyl)ethylamine (0.54 g, I.14 mmol) was hydrolyzed by the method of
example 34,
supra, to give 510 mg of the title compound as a white solid: 'H-NMR (1:1
CD3CN:D.O)
7.6-7.8 (4H), 7.40 (3H, m), 7.34 ( 1 H, d), 7.00 ( 1 H, s), 6.90 ( 1 H, d),
4.10 (2H, m), 4.00.( 1 H,
m), 2.83 (6H, m), 2.39 (2H, dd), 1.02 (6H, d); "C-NMR (1:1 CD~CN:DzO) 180.57,
160.77, 151.51, 136.47, 133.76, 133.55, 132.28, 129.68, 129.07, 127.78,
127.49, 126.32,
125.77, 121.76, 117.58, 113.18, 98.30, 71.48, 69.08, 53.71, 46.56, 44.59,
38.98, 33.10,
26.11, 25.92.
Example 36
Preparation of (R)-N-12-Hydroxv-3-(2-cyano-4-(3-
carbethoxypropy~phenoxy)propyll 1 1
dimethvl-2-l2-naphthyl)eth~rlamine Hydrochloride
15. (a) Ethyl 4-(3-cyano-4-hydroxyphenyl)butanoate
To an ice cooled solution of ethyl 4-(4-hydroxyphenyl)butanoate (16.73 g,
80.32 mmol) in
200 mL of CHCIs was added bromine (4.15 mL, 80.8 mmol). The cooling bath was
removed, and the reaction stirred at room temperature for 2 hours. The
reaction mixture
was then washed with water and brine, dried over sodium sulfate and
concentrated to give
22.3 g (96.6%) of ethyl 4-(3-bromo-4-hydroxyphenyl)butanoate as a crystalline
solid.
To a solution of ethyl 4-(3-bromo-4-hydroxyphenyl)butanoate ( 19.8 g, 69 mmol)
in
172 mL of N-methyl-2-pyrrolidinone was added CuCN (6.49 g, 72.4 mmol). The
solution
was heated to reflux for 4 hours then cooled to room temperature. The reaction
was diluted
with EtOAc and washed twice with 5% HCl and once with brine, then dried over
sodium
sulfate and concentrated. Purified on silica gel using 60:40 hexanes:EtOAc as
the elutant.
The yield of ethyl 4-(3-cyano-4-hydroxyphenyl)butanoate was 9.84 g (61%): 'H-
NMR
(CDCI3) 7.6? (IH, s), 7.24-7.29 (2H), 7.94 (1H, d), 4.14 (2H, q), 2.59 (2H,
dd), 2.34 (2H,
dd), 1.91 (2H, m), L28 (3H, t).
(b) Preparation of (R)-2-cyano-4-(3-carbethoxypropyl)phenyl glycidyl ether
Using the method of example 30(b), supra, ethyl 4-(3-cyano-4-
hydroxyphenyt)butanoate
(0.93 g, 4 mmol) and (R)-glycidyl nosylate ( 1.00 g, 3.86 mmol) were used to
prepare 0.74
g (66%) of the title compound as a white solid.
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
(c) Preparation of (R)-N-[2-Hydroxy-3-(2-cyano-4-(3-
carbethoxypropyl)phenoxy)propyl]-
1,1-dimethyl-2-(2-naphthyl)ethylamine Hydrochloride
Using the method of example 30(c), supra, (R)-2-cyano-4-(3-
carbethoxypropyl)phenyl
glycidyl ether (0.72 g, 2.48 mmol) and 1,1-dimethyl-2-(2-naphthyl)ethylamine
(0.52 g, 2.6
mmol) were was used to prepare 0.87 g (67%) of the title compound as a white
solid: 'H-
NMR (CDCh) 9.8 ( 1 H, br m}, 8.38 ( 1 H, br m), 7.73-7.8 (4H), 7.44 (2H, m),
7.36 ( 1 H, d),
7.22-7.28 (3H), 6.9 ( 1 H, d), 4.8 ( 1 H, br m), 4.22 (2H, m), 4.12 (2H, q),
3.35-3.6 (4H}, 2.53
(2H, dd), 2.26 (2H, dd), 1.85 (2H, m), 1.50 (6H, d), 1.25 (3H, t ).
Example 37
Preparation of (R)-N-f2-Hydroxv-3-(Z-cyano-4- 3-carboxynrop~phenoxy)propyll 1
1
dimethvl-2-(2-naphthyl)ethylamine Sodium Salt
(R)-N-[2-Hydroxy-3-(2-cyano-4-(3-carbethoxypropyl)phenoxy)propyl]-1,1-
dimethyl-2-(2-naphthyl)ethylamine (0.618 g, 1.17 mmol) was hydrolyzed by the
method of
example 33, supra, to give 555 mg (90%) of the title compound as a white
solid: 'H-NMR
(db DMSO) 7.86-7.94 (3H), 7.78 ( 1 H, s), 7.59 ( 1 H, d), 7.48-7.54 (3H), 7.42
( 1 H, d), 7.25
(1H, d), 4.22 (3H, m), 3.0-3.28 (4H, dd + br s), 2.60 (2H, dd), 2.23 (2H, dd),
1.8I (2H, m),
1.24 (6H, s).
Example 38
Preparation of (R)-N-f2-Hvdroxy-3-(2-cyano-3-f3-
carbethoxypropyl)phenoxy)propyl 1 1
dimethvl-2-(2-naphthvl)eth~lamine Hydrochloride
(a) Preparation of Ethyl 4-(2-cyano-3-hydroxyphenyl)butanoate
Starting from 2-fluoro-6-iodobenzonitrile, the title compound was prepared as
in example
32, supra, by replacing the fluoro group with a t-butoxy, replacing the iodo
group with the
3-carbethoxypropyl side chain via a Suzuki coupling and ester exchange, and
final removal
of the t-butyl group by acid. The title compound was obtained in 49% yield
over 4 steps:
'H-NMR (CDCI,) 7.84 ( 1 H, br s), 7.33 ( 1 H, dd), 6.87 ( 1 H, d), 6.82 ( 1 H,
d), 4.16 (2H, q),
51
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
2.83 (2H, dd), 2.40 (2H, dd), 2.02 (2H, m), 1.28 (3H, t); "C NMR (CDCh)
174.28, 159.84,
146.57, 134.18, 120.98, 115.81, 114.05, 100.09, 61.09, 33.80, 33.77, 25.75,
14.29.
(b) Preparation of (R)-2-cyano-3-(3-carbethoxypropyl)phenyl glycidyl ether
Using the method of example I(a), supra, ethyl 4-(2-cyano-3-
hydroxyphenyl)butanoate
(1.9 g, 7.33 mmol) and (R)-glycidyl nosylate (1.78 g, 7.6 mmol) were used to
prepare 1.70
g (80%) of the title compound as a white solid.
(c) Preparation of (R)-N-[2-Hydroxy-3-(2-cyano-3-(3-
carbethoxypropyl)phenoxy)propyl]-
1,1-dimethyl-2-(2-naphthyl)ethylamine Hydrochloride
Using the method of example I(b), supra, (R)-2-cyano-3-(3-
carbethoxypropyl)phenyl
glycidyl ether (0.8 g, 2.77 mmol) and 1,1-dimethyl-2-(2-naphthyl)ethylamine
(0.58 g, 2.9
mmol) were used to prepare 1.07 g (74%) of the title compound as a white
solid: 'H-NMR
(CDCl3) 9.81 (1H, br m), 8.40 (1H, br m), 7.72-7.82 (4H), 7.45 (2H, m), 7.35
(2H, m), 6.85
( 1 H, d), 6.81 ( 1 H, d), 4.81 ( 1 H, br s), 4.24 (2H, m), 4.12 (2H, q), 3.55
(2H, br m), 3.40 (2H,
s), 2.77 (2H, dd), 2.33 (2H, dd), 1.95 (2H, m), 1.51 (6H, d), 1.24 (3H, t); "C-
NMR (CDCl3)
173.15, 160.64, 147.29, 134.05, 133.42, 132.64, 132.16, 129.95, 128.99,
128.21, 127.95,
127.73, 126.42, 126.17,122.26, 115.62, 110.50, 102.70, 70.94, 65.79, 61.68,
60.63, 45.31,
44.46, 33.74, 33.66, 25.77, 23.36, 23.18, 14.42.
Example 39
Preparation of (R)-N-f2-Hydroxy-3-(2-cyano-3-l3-carboxy roovl)phenox~propyll-1
1-
dimethyl-2-(2-naphth~rl)et~lamine Sodium Salt
(R)-N-[2-Hydroxy-3-(2-cyano-3-(3-carbethoxypropyl)phenoxy)propyl]-1,1-
dimethyl-2-(2-naphthyl)ethylamine (0.687 g, 1.3 mmol) was hydrolyzed by the
method of
example 33, supra, to give 502 mg (80%) of the title compound as a white
solid: 'H-NMR
(D20) 7.00 (SH, m), 6.70 (3H, m), 6.53 ( 1 H, d}, 6.22 ( 1 H, d), 3.70 ( 1 H,
br s), 3.52 (2H, br
s), 2.21-2.37 (6H), 1.92 (2H, m), 1.54 (2H, m), 0.53 (SH, br s); "C-NMR (DZO)
176.89,
154.86, 142.43, 130.24, 129.08, 127.58, 126.29, 123.66, 123.13, 121.91,
121.67, 120.21,
119.65, 116.37, 110.99, 104.04, 94.82, 65.87, 63.21, 60.58, 47.80, 40.61,
38.94, 31.64,
28.23, 21.29, 20.35.
52
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Example 40
R)-N-f2-Hvdroxv-3-l2-cvano-4-(2-carbethoxy-traps-ethylene phenoxy)nrowll-1 1
dimethyl-2-l2-naphth~)ethylamine
(a) Ethyl-3-(2-cyano-4-hydroxyphenyl)propenoate
A solution of 158.1 g (0.8 mol) of 2-cyano-4-bromophenol, 88.1 lg (0.88 mol)
of ethyl
methacrylate, 36.5 g (0.12 mol) of tri-o-tolylphosphine and 110.6 g (0.8 mol)
of potassium
carbonate in 1000 mL of acetonitrile and 300 mL of water was stirred and
degassed three
times by alternately evacuating the flask under vacuum and then filling the
flask with
nitrogen. Under nitrogen 9 g (0.04 mol) of palladium(II) acetate was added and
the mixture
refluxed for 7 h. The reaction was diluted with 500 mL of water and the pH
adjusted to 3-4
with concentrated hydrochloric acid. The mixture was then extracted with ethyl
acetate.
The ethyl acetate solution was dried over sodium sulfate, filtered and
concentrated to
approximetely 500 mL. The resulting slurry was dissolved in 4 L of MeCN,
heated to reflux
and then poured through a 1 inch celite pad. The filtrate was concentrated to
about 1.5 L
and allowed to cool to room temperature over night. The solution was filtered
and the solid
dried under vacuum to yield 150 g of a white solid (86%).
Following the procedures descrived for Example 30 and 31 the title compound
was
obtained.
Example 41
Inhalant Formulation
A compound of Formula (I) ( 1 mg to 100 mg) is aerosolized from a metered dose
inhaler to deliver the desired amount of drug per use.
53
- .=~.r.~...~..~,- ._... _~..-~. . _ ~..~......_ _...__.~.~.....~___...
CA 02327279 2000-10-03
WO 99/51569 PCT/US99/07722
Example 42
Tablet Formulation
Tablets/InQredients Per Tablet
i. Active ingredient 40 mg
(Cmp. of Formula(I))
2. Corn Starch 20 mg
3. Alginic acid 20 mg
4. Sodium Alginate 20 mg
5. Mg stearate . 13 mg
Procedure for tablet formulation
Ingredients l, 2, 3 and 4 are blended in a suitable mixer/blender. Sufficient
water
is added portion-wise to the blend with careful mixing after each addition
until the mass is
of a consistency to permit its conversion to wet granules. The wet mass is
converted to
granules by passing it through an oscillating granulator using a No. 8 mesh
(2.38 mm)
screen. The wet granules are then dried in an oven at 140°F
(60°C) until dry. The dry
granules are lubricated with ingredient No. 5, and the lubricated granules are
compressed
on a suitable tablet press.
Example 43
Parenteral Formulation
A pharmaceutical composition for parenteral administration is prepared by
dissolving an appropriate amount of a compound of Formula (I) in polyethylene
glycol with
heating. This solution is then diluted with water for injections (to 100 ml).
The solution is
then rendered sterile by filtration through a 0.22 micron membrane filter and
sealed in
sterile containers.
All publications, including but not limited to patents and patent applications
cited
in this specification are herein incorporated by reference as if each
individual publication
were specifically and individually indicated to be incorporated by reference
as though fully
set forth.
54
